

Curriculum Vitae

Personal information **Ingo Schmidt-Wolf**

Work experience

1986	Academic assistant, West German Cancer Center Essen, Essen University Hospital
1986 – 1988	Ward physician at the Clinic for Respiratory Diseases and Allergies Norderney as part of the further education in internal medicine
1988 – 1991	Fellow at the Department of Immunology und Fellow at the Bone Marrow Transplantation Program, Stanford University, U.S.A.
1991 – 1996	Academic assistant of the department internal medicine with a focus on hematology/oncology of the FU Berlin or HU Berlin
1992	Additional specialization Allergology
1995	Specialist internal medicine
1996	Specialization hematology und medical oncology; clinical senior physician Department Internal Medicine with focus on Hematology/Oncology, Virchow-Klinikum, Humboldt-University Berlin, Director: Professor Dr. D. Huhn
1997	Vocation as C3-professor for hematology and internal oncology, Medical clinic and Polyclinic I, Rheinische Friedrich-Wilhelms-University Bonn
since 2002	Additional management of the Center for Integrated Oncology (CIO) at Bonn
2008 – 2013	Parallel to the work as Director of the CIO senior physician and deputy clinical director of the newly created Department of Medicine III of the University Hospital Bonn
since 2013	Solely activity as Director of the Center for Integrated Oncology at Bonn

Education and training

1979 – 1983	Study of Medicine at the University of Essen, Germany
1983 – 1986	Study of Medicine at the Bayerische Julius-Maximilians-University of Würzburg
1986 Maximilians-	State examination Medicine at the Bayerische Julius-

Additional information

Publications

- **Schmidt-Wolf** IGH, Brandhorst D, Hertenstein C, Wetter O. Results with a modified human myeloma stem cell assay. Klin Wochenschr 61:1101-1103 (1983)

IF: 0

- **Schmidt-Wolf** IGH, Aihara M, Negrin, RS, Blume KG, Chao NJ. Lymphokine-activated killer cell activity after cryopreservation. J Immunol Meth 125:185-189 (1989)

IF: 1.9

- **Schmidt-Wolf** IGH, Fischer J. Einfluss eines Aufenthaltes im Nordseeklima auf die Lymphozytensubpopulationen im peripheren Blut bei Patienten mit exogen allergischem Asthma bronchiale und chronischer Bronchitis. Pneumologie 44, 241-242 (1990)

IF: 0.3

- Fischer J, **Schmidt-Wolf** IGH, Raschke F. Einfluss eines mehrwöchigen Aufenthaltes im Nordseeklima auf die Lymphozytensubpopulationen bei Patienten mit Neurodermitis und Atemwegserkrankungen. Z Phys Med Baln Med Klim 19:320-324 (1990)

IF:1.8

- Negrin RS, Kiem HP, **Schmidt-Wolf** IGH, Blume KG, Cleary ML. Use of the polymerase chain reaction to monitor the effectiveness of tumor cell purging with antibodies and complement. Blood 77(3):654 -660 (1991)

IF: 17.5

- Aihara M, Aihara Y, Schmidt -Wolf G, **Schmidt-Wolf** IGH, Sikic BI, Blume KG, Chao NJ. A combined approach for purging multidrug resistant leukemic cell lines in bone marrow, using a monoclonal antibody and chemotherapy. Blood 77(9):2079 -2084 (1991)

IF: 17.5

- **Schmidt-Wolf** IGH, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse / human lymphoma model to evaluate cytokine-induced killer cells with potent anti-tumor cell activity. J Exp Med 174(1):139-149 (1991; cited in Science 259:1463 (1993))

IF: 11.7

- Beyer J, Kleider S, Strohscheer I, Schwerdtfeger R, Schwella N, **Schmidt-Wolf** I, Schmid HJ, Siegert W. Organ Toxicity of High-Dose Carboplatin, Etoposide and Ifosfamid. Bone Marrow Transplantation 10:9-9 (1992).

IF: 4.7

- **Schmidt-Wolf** IGH, Aihara M, Negrin RS, Blume KG, Chao NJ. In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation. Transfusion 32(1):42-45 (1992)

IF: 2.8

- Schlegel PG, Schmidt-Wolf G, **Schmidt-Wolf** IGH, Kwak LW, Chao NJ. Lymphokine-activated killer cell activity against autologous lymphoma cells following bone marrow transplantation. Cancer Research, Therapy and Control Vol.3:145 -152 (1993)

IF: 0.5

- **Schmidt-Wolf** IGH, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor recognition of cytokine-induced killer cells. Experimental Hematology 21:1673-1679 (1993)

IF: 2.8

- **Schmidt-Wolf** IGH, Dejbakhsh-Jones S, Ginzton N, Greenberg P, Strober S. T cell subsets and suppressor cells in human bone marrow. Blood, 80(12):3242 -3250 (1992)

IF: 17.5

- **Schmidt-Wolf** IGH, Liang O, Dejbakhsh-Jones S, Wang H, Cheng L, Holm B, Bell R, Strober S. Homogeneous antigen receptor beta chain genes in cloned CD4+ - CD8+ - alpha, beta+ T suppressor cells. J Immunol. 151:5348-5353 (1993)

IF: 4.9

- **Schmidt-Wolf** IGH, Schwerdtfeger R, Schwella N, Gallardo J, Schmid H, Huhn D, Siegert W. Diffuse pulmonary alveolar hemorrhage after allogeneic bone marrow transplantation. Ann Hematol, 67:139-141 (1993)

IF: 2.9

- Schwella N, Schwerdtfeger R, **Schmidt-Wolf** IGH, Schmid H, Siegert W. Pneumococcal arthritis after allogeneic bone marrow transplantation. Bone Marrow Transplantation 12:165-166 (1993)

IF: 4.7

- Lefterova P, Negrin R, Neubauer A, Huhn D, Blume K, **Schmidt-Wolf** IGH. Efficient generation and characterization of tumor cell subclones with different adhesion pathways involved in cell lysis. Haematologica, 78(6), 353 -358 (1993)

IF: 7.1

- Schwella N, Koenig V, Schwerdtfeger R, **Schmidt-Wolf** IGH, Schmid H, Riess H, Siegert W. Ondansetron for efficient emesis control during total body irradiation. Bone Marrow Transplantation 13, 169-171 (1994)

IF: 4.7

- **Schmidt-Wolf** IGH, Lefterova P, Johnston V, Neubauer A, Huhn D, Negrin R, Blume KG. Propagation of T cells with NK cell marker. Br J Haematol 87, 453-458 (1994)

IF: 5.5

- Schwella N, Schwerdtfeger R, Koenig V, Blasczyk R, Schmid H, **Schmidt -Wolf** IGH, Henze G, Siegert W. Allogeneic bone marrow transplantation for recurrence of leukemia after autologous bone marrow transplantation. Transplantation 57, 1263-1265 (1994)

IF: 4.3

- **Schmidt-Wolf** IGH, Neubauer A, Finke S, Csipai M, Wittig B, Huhn D. Interleukin-7 gene therapy for patients with metastatic colon cancer, renal cell cancer, malignant melanoma or lymphoma. Human Gene Ther 5(9), 1161-1168 and 1197 (1994)

IF: 4.3

- Schmidt-Wolf G, **Schmidt-Wolf** IGH. Human cancer and gene therapy. Ann Hematol 69(6), 273-279 (1994)

IF: 2.9

- Scheffold C, Brandt K, Johnston V, Lefterova P, Huhn D, Neubauer A, Negrin RS, **Schmidt-Wolf** IGH. Potential of autologous cytokine induced killer cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplantation 15, 33-39 (1995)

IF: 4.7

- Schmidt-Wolf G, **Schmidt-Wolf** IGH. Cytokines and gene therapy. Immunol Today 16(4), 173-175 (1995)

IF: 12.9

- Schmidt-Wolf GD, **Schmidt-Wolf** IGH. Bone marrow and clinical gene therapy. J Hematother 4, 551-561 (1995)

IF: 3.0

- Schmidt-Wolf G, **Schmidt-Wolf** IGH. Cytokines and clinical gene therapy. Europ J Immunol 25(4), 1137-1140 (1995)

IF: 4.4

- Csipai M, Lefterova P, Finke S, Johnston V, Scheffold C, Huhn D, **Schmidt-Wolf** IGH. Effects of interleukin-7 on proliferation of tumor cells. Cancer Research, Therapy and Control (5), 11-16 (1996)

IF: 0.5

- **Schmidt-Wolf** IGH, Lefterova P, Johnston V, Scheffold C, Csipai M, Mehta B, Tsuruo T, Huhn D, Negrin RS. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 169, 85-90 (1996)

IF: 4.1

- **Schmidt-Wolf** IGH, Grimm B, Lefterova P, Johnston V, Scheffold C, Huhn D, Serke S. Propagation of large numbers of cells of a human mixed-lineage T-lymphoid/myeloid. Br J Haematol 90, 512-517 (1995)

IF: 5.5

- Mehta BA, **Schmidt-Wolf** IGH, Weissman IL, Negrin RS. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells. Blood 86(9), 3493-3499 (1995)

IF: 17.5

- Finke S, Trojanec B, Moeller P, Schadendorf D, Neubauer A, Huhn D, **Schmidt-Wolf** IGH. Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interleukin-7 gene. Cancer Gene Ther 4(4), 260-268 (1997)

IF: 4.5

- Lefterova P, **Schmidt-Wolf** IGH. Coexpression of lymphoid and myeloid markers on cell surfaces. Leukemia and Lymphoma 26, 27-33 (1997)

IF: 3.0

- Schmidt-Wolf GD, Negrin RS, **Schmidt-Wolf** IGH. Activated T cells and cytokine-induced CD3+CD56+ killer cells. Annals Hematol 74, 51-56 (1997)

IF: 2.9

- Schriever F, Korinth D, Salahi A, Lefterova P, **Schmidt-Wolf** IGH, Behr SI. Human T lymphocytes bind to germinal centers of human tonsils via integrin alpha4/VCAM-1 and FA-1alpha/ICAM-1 and -2. Europ J Immunol 27, 35-39 (1997)

IF: 4.4

- Ebert O, Finke S, Salahi A, Herrmann M, Trojanec B, Lefterova P, Wagner E, Kircheis R, Neubauer A, Huhn D,

Schriever F, Wittig B, **Schmidt-Wolf** IGH. Lymphocyte apoptosis: Induction by gene transfer techniques. Gene Therapy 4, 296-302 (1997)

IF: 4.1

- Finke S, Trojanek B, Lefterova P, Csipai M, Wagner E, Kircheis R, Neubauer A, Huhn D, Wittig B, **Schmidt-Wolf** IGH. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Ther 5, 31-39 (1998)

IF: 4.1

- Mueller M, Scheffold C, Lefterova P, Huhn D, Neubauer A, **Schmidt-Wolf** IGH. Potential of autologous immunologic effector cells for the prediction of progression of disease of patients with chronic myeloid leukemia. Leukemia and Lymphoma 31, 335-341 (1998)

IF: 3.0

- Mann B, Gratchev A, Riede E, **Schmidt-Wolf** IGH, Trojanek B, Moyer MP, Hanski C, Buhr HJ. Beta-catenin overexpression in metastasized colorectal carcinomas - an important mechanism during the progression of the disease? Langenbecks Arch Chir I, Forumsband 1998, 303-306 (1998)

IF: 2.1

- Schmidt-Wolf GD, **Schmidt-Wolf** IGH. Cancer and gene therapy. Ann Hematol 73, 207-218 (1996)

IF: 2.9

- Zoll B, Lefterova P, Finke S, Trojanek B, Ebert O, Micka B, Roigk K, Fehlinger M, Schmidt-Wolf GD, Huhn D, **Schmidt-Wolf** IGH. Generation of cytokine-induced killer (CIK) cells using exogenous interleukin-2 (IL-2), -7 (IL-7) or -12 (IL-12). Cancer Immunol Immunother 47(4), 221-226 (1998)

IF: 5.4

- Glasmacher A, Molitor E, Hahn C, Bomba K, Ewig S, Leutner C, Wardelmann E, **Schmidt-Wolf** IGH, Mezger J, Marklein G, Sauerbruch T. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 12, 1338-1343 (1998)

IF: 8.7

- Flieger D, Spengler U, Beier I, Kleinschmidt R, Hoff A, Varvenne M, Sauerbruch T, **Schmidt-Wolf** IGH. Enhancement of ADCC by combination of cytokines. Hybridoma 18(1), 63-68 (1999)

IF: 0.3

- Mann B, Gratchev A, Böhm C, Hanski ML, Foss HD, Demel G, Trojaneck B, **Schmidt-Wolf** IGH, Stein H, Riecken EO, Buhr HJ, Hanski C. FasL is more frequently expressed in liver metastases than in matched primary carcinomas. *Brit J Cancer* 79 (7-8):1262-1269 (1999)

IF: 5.8

- Glasmacher A, Hahn C, Molitor E, Sauerbruch T, **Schmidt-Wolf** IGH, Marklein G. Fungal surveillance cultures during antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. *Mycoses* 42:395-402 (1999)

IF: 3.6

- Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, Sauerbruch T, Marklein G, **Schmidt-Wolf** IGH. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. *Mycoses* 42:443-451 (1999)

IF: 3.6

- Searle J, Finke S, Trojaneck B, Lefterova P, Micka B, Roigk K, Fehlinger M, Schmidt-Wolf G, Polack A, Huhn D, **Schmidt-Wolf** IGH. Effects of human interleukin-2 and interleukin-12 on proliferation of tumor and immunologic effector cells. *Cancer Res Ther Control* 10(1-2) (1999)

IF: 0.5

- Glasmacher A, Hahn C, Molitor E, Sauerbruch T, **Schmidt-Wolf** IGH. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. *Mycoses* 42, 591-600 (1999)

IF: 3.6

- **Schmidt-Wolf** IGH, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D. Phase I clinical study applying autologous immunologic effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. *Brit J Cancer* 81(6):1009-1016 (1999)

IF: 5.8

- Lefterova P, Märten A, Buttgereit P, Weineck S, Micka B, Scheffold C, Huhn D, **Schmidt-Wolf** IGH. Use of a bispecific anti-CD3xCD19 antibody for targeting of CD3+CD56+ human cytotoxic cells against CD19+ leukemia and lymphoma cells. *Cancer Res Ther Contr* 10:205-215 (1999)

IF: 0.5

- Ebert O, Röpke G, Märten A, Lefterova P, Micka B, Buttgereit P, Niemitz S, Trojanek B, Schmidt-Wolf G, Huhn D, Wittig B, **Schmidt-Wolf** IGH. TNF-alpha secretion and apoptosis of lymphocytes mediated by gene transfer. Cytokines, Cellular & Mol Ther 5(3):165-173 (1999)

IF: 1.3

- Caspari R, Jungck M, Lamberti C, **Schmidt-Wolf** IGH, Friedl W, Propping P. Diagnostik hereditärer kolorektaler Karzinome. DMW 125:153-158 (2000)

IF: 0.6

- Lamberti C, Jungck M, Caspari R, **Schmidt-Wolf** IGH, Sauerbruch T. Therapie und Nachsorge der FAP und des HNPCC. DMW 125:189-191 (2000)

IF: 0.6

- Schroers R, Sinha I, Segall H, **Schmidt-Wolf** IGH, Rooney CM, Brenner MK, Sutton RE, Chen SY. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Molecular Therapy 1(2), 171-179 (2000)

IF: 9.0

- Micka B, Trojanek B, Niemitz S, Lefterova P, Kruopis S, Huhn D, Wittig B, Schadendorf D, **Schmidt-Wolf** IGH. Comparison of non-viral transfection methods in melanoma primary cultures. Cytokine 12(6), 828-833 (2000)

IF: 3.0

- Märten A, Schöttker B, Ziske C, Weineck S, Buttgereit P, Huhn D, Sauerbruch T, **Schmidt-Wolf** IGH. Increase of the immunostimulatory effect of dendritic cells by pulsing with CA-19-9 protein. J Immunother 23(3):304-310 (2000)

IF: 4.1

- von Ruecker A, **Schmidt-Wolf** IGH. Strategies to evaluate catabolism and metabolic stress by immunological variables. Clinical Nutrition 19(2):147-156 (2000)

IF: 6.4

- Lefterova P, Märten A, Buttgereit P, Schakowski F, Micka B, Scheffold C, **Schmidt-Wolf** IGH. Induction of apoptosis in B lymphoma cells by activation with CD40L. Acta Haematologica 103(3):168-171 (2000)

IF: 1.3

- Flieger D, Spengler U, Beier I, Kleinschmidt R, Sauerbruch T, **Schmidt-Wolf** IGH. Augmentation of 17-1A induced

ADCC by the triple cytokine combination of IFN-alpha, IL-2 and IL-12. J Immunother 23(4):480-486 (2000)

IF: 4.1

- Lefterova P, Märten A, Buttgereit P, Weineck S, Huhn D, Scheffold C, **Schmidt-Wolf** IGH. Targeting of NK-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody dependent cellular cytotoxicity. J Immunother 23(3):304-310 (2000)

IF: 4.1

- Trojaneck B, Niemitz S, Micka B, Lefterova P, **Schmidt-Wolf** IGH. Establishment and characterization of colon carcinoma and renal cell carcinoma primary cultures. Cancer Biother & Radiopharm 15(2):169-174 (2000)

IF: 2.3

- Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, Klingmüller D, Scheffold C, von Rücker A, Sauerbruch T, **Schmidt-Wolf** IGH Increase in the immunostimulatory effect of dendritic cells by pulsing with serum derived from pancreatic and colorectal cancer patients. International Journal of Colorectal Disease 15:197-205 (2000)

IF: 2.1

- Flieger D, Renoth S, Beier I, Sauerbruch T, **Schmidt-Wolf** IGH. Mechanism of cytotoxicity induced by the chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20 expressing lymphoma cell lines. Cellular Immunology 204: 55-63 (2000)

IF: 4.1

- Flieger D, Kufer P, Beier I, Sauerbruch T, **Schmidt-Wolf** IGH. A bispecific single-chain antibody directed against EpCAM/CD3 mediates efficient cytotoxicity by cytokine-induced killer cells against EpCAM expressing tumor cells. Cancer Immunol Immunother 49:441-448 (2000)

IF: 5.4

- Flieger D, Spengler U, Beier I, Sauerbruch T, **Schmidt-Wolf** IGH. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the ADCC of monoclonal antibody 17-1A. Zeitschrift für Gastroenterologie 38:615-622 (2000)

IF: 1.4

- Zoll B, Lefterova P, Ebert O, Huhn D, von Rücker A, **Schmidt-Wolf** IGH. Modulation of cell surface markers on NK-like T lymphocytes by using interleukin-2, -7 or -12 in vitro stimulation. Cytokine 12 (9):1385-1390 (2000)

IF: 3.0

- Schlegel U, **Schmidt-Wolf** IGH, Deckert M. Primary CNS lymphoma: Clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sciences 181(1-2):1-12 (2000)

IF: 3.1

- Röpke G, Ebert O, Märten A, Lefterova P, Micka B, Buttgereit P, Finke S, Trojanek B, Schmidt-Wolf G, von Rücker A, Huhn D, Wittig B, **Schmidt-Wolf** IGH. Increase in proliferation rate and normalization of TNF-alpha secretion by blockage of gene transfer induced apoptosis using low dose cyclosporine. Cancer Gene Ther 7(11):1411-1413 (2000)

IF: 4.5

- Lefterova P, Schakowski F, Scheffold C, Huhn D, **Schmidt-Wolf** IGH. Expansion of CD3+CD56+ cytotoxic cells from patients with CLL: In vitro efficacy. Haematologica 85(10):1108-1109 (2000)

IF: 7.1

- Buttgereit P, Weineck S, Röpke G, Märten A, Brand K, Heinicke T, Caselmann WH, Huhn D, **Schmidt-Wolf** IGH. Efficient gene transfer into lymphoma cells using adenoviral vectors combined with lipofection. Cancer Gene Ther 7(8):1145-1155 (2000)

IF: 4.5

- Flieger D, Spengler U, Beier I, Sauerbruch T, **Schmidt-Wolf** IGH. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the IL-4 suppresses the cytokine-induced antibody dependent cellular cytotoxicity of the monoclonal antibodies 17-1A and BR55-2. Cytokine 12(6):756-761 (2000)

IF: 3.0

- Scheffold C, Schöttker B, Lefterova P, Csipai M, Glasmacher A, Huhn D, Neubauer A, **Schmidt-Wolf** IGH. Increased sensitivity of myeloid leukemia cell lines: Potential of lovastatin as a bone marrow purging agent. Acta Haematol 104(2-3):72-79 (2000)

IF: 1.2

- Ziske C, Märten A, Schöttker B, Weineck S, Buttgereit P, Schakowski F, Gorschlüter M, von Rücker A, Scheffold C, Chao N, Sauerbruch T, **Schmidt-Wolf** IGH. DC directly trigger NK-like T lymphocytes: Reversal of resistance of pancreatic carcinoma cells by co-culturing of NK-like T cells with DC pulsed with tumor derived RNA and CA 19-9. Mol

Ther 3(1):54-60 (2001)

IF: 9.0

- Flieger D, Hoff A, Sauerbruch T, **Schmidt-Wolf** IGH. Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on EpCAM and Lewis^Y antigen expression. Clin Exp Immunol 123:9-14 (2001)

IF: 3.5

- Wittig B, Märten A, Dorbic T, Weineck S, Min H, Lefterova P, Niemitz S, Trojanek B, Flieger D, Kruopis S, Löffel J, Neubauer A, Albers P, Müller SC, Sauerbruch T, Bieber T, Huhn D, **Schmidt-Wolf** IGH. Therapeutic vaccination against metastatic carcinoma by autologous tumor cells transfected with interleukin-7, GM-CSF and immunostimulatory oligonucleotides: Preclinical results and outcome of a first clinical phase I/II trial. Human Gene Therapy 12(3):267-278 (2001)

IF: 4.3

- Ziske C, Meybehm M, Sauerbruch T, **Schmidt-Wolf** IGH. Littoral cell angioma as a rare cause of splenomegaly. Annals of Hematology 80(1):45-48 (2001)

IF: 2.9

- Märten A, Ziske C, Schöttker B, Weineck S, Buttgereit P, Schakowski F, von Rücker A, Scheffold C, Sauerbruch T, **Schmidt-Wolf** IGH. Transduction of DC with the CIITA gene: Increase of immunostimulatory activity of DC. Cancer Gene Therapy 8/3:211-219 (2001)

IF: 4.5

- Pels H, Glasmacher A, **Schmidt-Wolf** IGH, Schlegel U. Therapie primärer cerebraler Lymphome. Aktuelle Neurologie 28:189-194 (2001)

IF: 0.3

- Schakowski F, Gorschlüter M, Junghans C, Schroff M, Buttgereit P, Ziske C, Schöttker B, König-Merediz SA, Sauerbruch T, Wittig B, **Schmidt-Wolf** IGH. A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther 3(5):793-800 (2001)

IF: 9.0

- Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, **Schmidt-Wolf** IGH, Helmstaedter C, Fließbach K, Deckert-Schlüter M, Van Roost D, Fimmers R, Bode U, Klockgether T. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry 71(1):118-122 (2001)

IF: 8.2

- Märten A, Ziske C, Weineck S, Buttgereit P, Lefterova P, Klingmüller D, von Rücker A, Scheffold C, Sauerbruch T, **Schmidt-Wolf** IGH. Priming of NK-like T lymphocytes by addition of dendritic cells pulsed with CEA protein and patient serum containing CEA. *Cancer Research, Therapy & Control* 11:157-166 (2001)

IF: 0.5

- Gorschlüter M, Glasmacher A, Hahn C, Schakowski F, Ziske C, Molitor E, Marklein G, Sauerbruch T, **Schmidt-Wolf** IGH. Clostridium difficile infection in patients with neutropenia. *Clinical Infectious Diseases* 33:786-791 (2001)

IF: 8.3

- Gorschlüter M, Ziske C, Glasmacher A, **Schmidt-Wolf** IGH. Current clinical and laboratory strategies to augment the efficiency of immunotherapy in multiple myeloma. *Clin Cancer Research* 7(8):2195-2204 (2001)

IF: 10.1

- Buttgereit P, Schakowski F, Märten A, Brand K, Renoth S, Ziske C, Schöttker B, Ebert O, Schroers R, **Schmidt-Wolf** IGH. Effects of adenoviral wild-type p53 gene transfer in p53- mutated lymphoma cells. *Cancer Gene Therapy* 8(6):430-439 (2001)

IF: 4.5

- Gorschlüter M, Glasmacher A, Hahn C, Leutner C, Marklein G, Remig J, **Schmidt-Wolf** IGH, Sauerbruch T. Severe abdominal infections in neutropenic patients. *Cancer Invest* 19(7):669-677 (2001)

IF: 2.4

- Märten A, Renoth S, von Lilienfeld-Toal M, Buttgereit P, Schakowski F, Glasmacher A, Sauerbruch T, **Schmidt-Wolf** IGH. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiosyncratic dendritic cells. *Haematologica* 86(10):1029-1037 (2001)

IF: 7.1

- von Lilienfeld-Toal M, Ebert O, Theuerkauf I, Glasmacher A, **Schmidt-Wolf** IGH. Small bowel obstruction in acute myelogenous leukemia: Stenosis or paralysis? *Annals Hematol* 80:611-613 (2001)

IF: 2.9

- Korfel A, Finke J, **Schmidt-Wolf** IGH, Thiel E. 5. Report on

workshop: Primary CNS lymphoma. Ann Hematol. 80 Suppl 3:B20-23 (2001)

IF: 2.9

- Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, von Rücker A, Sauerbruch T, **Schmidt-Wolf** IGH. Interactions between DC and CIK cells lead to an activation of both populations. J Immunother 24(6):502-510 (2001)

IF: 4.1

- Märten A, Greten T, Ziske C, Schöttker B, Renoth S, Schöttker B, Buttgereit P, Schakowski F, von Rücker A, Sauerbruch T, **Schmidt-Wolf** IGH. Generation of activated and antigen-specific T cells with cytotoxic activity after coculture with dendritic cells. Cancer Immunol Immunother 51:25-32 (2002)

IF: 5.4

- Gorschlüter M, Hahn C, Ziske C, Mey U, Schöttker B, Molitor E, Becker S, Marklein G, Sauerbruch T, **Schmidt-Wolf** IGH, Glasmacher A. Low frequency of enteric infections by salmonella, shigella, yersinia and campylobacter in patients with acute leukemia. Infection 30(1):22-25 (2002)

IF: 3.0

- Schmidt-Wolf G, **Schmidt-Wolf** IGH. Immunomodulatory gene therapy for haematological malignancies. Brit J Haematol 117(1):23-32 (2002)

IF: 5.5

- Ziske CG, Schöttker B, Gorschlüter M, Mey U, Kleinschmidt R, Schlegel U, Sauerbruch T, **Schmidt-Wolf** IGH. Acute transient encephalopathy after paclitaxel infusion: report of three cases. Annals of Oncology 13:629-631 (2002)

IF: 18.3

- Layer G, Sander W, Träber F, Block W, Ziske C, **Schmidt-Wolf** IGH, Schild HH, Ko Y. Magnetic resonance findings in the bone marrow of the lumbar spine in patients during G-CSF therapy in comparison to malignant bone marrow infiltrations. In press, Cancer

IF: 5,7

- Springer W, Decker D, Daufeldt S, Decker P, **Schmidt-Wolf** IGH, Hirner A, von Ruecker A. Human growth hormone down-regulates apoptosis and increases superoxide production in neutrophils from patients undergoing major vascular surgery. In press, Annals of Surgery

IF: 10.1

- Gorschlüter M, Marklein G, Hofling K, Clarenbach R, Baumgartner S, Hahn C, Ziske C, Mey U, Heller R, Eis-Hübinger AM, Sauerbruch T, **Schmidt-Wolf** IGH, Glasmacher A. Abdominal infections in patients with acute leukaemia: a prospective study applying ultrasonography and microbiology. *Brit J Haematol* 117(2):351-358 (2002)

IF: 5.5

- Buttgereit P, **Schmidt-Wolf** IGH. State-of-the-art review. Gene therapy of lymphoma. *J Hematother & Stem Cell Res* 11(3): 457-467 (2002)

IF: 2.5

- **Schmidt-Wolf** IGH, Rockstroh JK, Schlegel U, Pels H, Weiss R, Huhn D. New aspects in the treatment of AIDS-related lymphoma. *Eur J Med Research* 7(7):295-303 (2002)

IF: 1.8

- Reinhard G, Märten A, Kiske M, Feil F, Bieber T, **Schmidt-Wolf** IGH. Generation of dendritic cell-based vaccines for cancer therapy. *Brit J Cancer* 86:1529-1533 (2002)

IF: 5.8

- Märten A, Renoth S, **Schmidt-Wolf** IGH. Increase of the stimulatory effect of dendritic cells by pulsing with apoptotic bodies transfected with the MHC class II gene. *Mol Immunol* 39:395-398 (2002)

IF: 3.6

- Ziske C, Gorschlüter M, Mey U, Offergeld R, Glasmacher A, **Schmidt-Wolf** IGH. Sequential high-dose chemotherapy with autologous stem cell support in patients with limited-stage small cell lung cancer. *Anticancer Research* 22 (6) 3723-3726 (2002)

IF: 2.0

- Märten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M, Schöttker B, Ziske C, Engelhart S, Hanfland P, Krizek L, Faber C, von Rücker A, Müller S, Sauerbruch T, **Schmidt-Wolf** IGH. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: Preclinical results and outcome of a first clinical phase I/II trial. *Cancer Immunol Immunother* 51:637-644 (2002)

IF: 5.4

- Abken H, Hombach A, Reinhard G, Märten A, Schlimper C, Glasmacher A, Bieber T, **Schmidt-Wolf** IGH. Cellular

immunotherapy after autologous hematopoietic stem cell transplantation: Experimental strategies and clinical experiences. *Leukemia & Lymphoma* 44(4): 583-592 (2003)

IF: 3.0

- Mey U, Glasmacher A, Hahn C, Gorschlüter M, Ziske B, Mergelsberg M, Sauerbruch T, **Schmidt-Wolf** IGH. Evaluation of an ultrasound-guided technique for central venous access via the internal jugular vein in 493 patients. *Supp Care Cancer* 11:148-155 (2003)

IF: 2.6

- **Schmidt-Wolf** IGH, Rockstroh JK, Schüller H, Hirner A, Grohe C, Müller-Hermelink HK, Huhn D. Malignant thymoma: Current status of classification and multimodality treatment. *Annals Hematol* 82(2):69-76 (2003)

IF: 2.9

- Fließbach K, Urbach H, Helmstaedter C, Pels H, Glasmacher A, Kraus JA, Klockgether T, **Schmidt-Wolf** IGH, Schlegel U. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. *Archives of Neurology* 60:563-568 (2003)

IF: 7.4

- Mey U, Strehl J, Gorschlüter M, Ziske C, Sauerbruch T, Glasmacher A, Pralle H, **Schmidt-Wolf** IGH. Recent advances in the treatment of hairy cell leukemia. *The Lancet Oncology* 4: 86-94 (2003); IF 24,7

IF: 33.8

- Schmidt-Wolf GD, **Schmidt-Wolf** IGH. Non-viral and hybrid vectors in human gene therapy: an update. *Trends Molecular Medicine* 9(2):67-72 (2003)

IF: 11.1

- Mey U, Gorschlüter M, Ziske C, Kleinschmidt R, Glasmacher A, **Schmidt-Wolf** IGH. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. *Anticancer Drugs* 14:233-238 (2003)

IF: 2.3

- Märten A, Renoth S, Heinicke T, Albers P, Pauli A, von Lilienfeld-Toal M, Caspari R, Flieger D, Hanfland P, von Rücker A, Eis-Hübinger AM, Müller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, **Schmidt-Wolf** IGH. Allogeneic dendritic cells fused with tumor cells: Preclinical

results and outcome of a first clinical phase I/II trial in patients with renal cell carcinoma. Hum Gene Ther 4(5):483-494 (2003)

IF: 4.3

- Gorschlüter M, Hahn C, Fixon A, Mey U, Ziske C, Molitor E, Horre R, Sauerbruch T, Marklein G, **Schmidt-Wolf** IGH, Glasmacher A. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with haematologic malignancies: a randomized comparison. Supportive Care in Cancer 11:362-370 (2003)

IF: 2.6

- Schmidt-Wolf GD, **Schmidt-Wolf** IGH. Gene therapy for hematological malignancies. Clinical and Experimental Medicine 3 (1):4-14 (2003)

IF: 2.6

- Palmedo H, Manka-Waluch A, Albers P, **Schmidt-Wolf** IGH, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers H, Knapp FF, Guhlke S, Biersack HJ. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 HEDP. J Clin Oncol 21(15):2869-2875 (2003)

IF: 33.0

- Steigerwald R, Rabe C, Schmitz V, **Schmidt-Wolf** IGH, Alt M, Caselmann WH. Requirements for adeno-associated virus-derived non-viral vectors to achieve stable and site-specific integration of plasmid DNA in liver carcinoma cells. Digestion 68:13-23 (2003)

IF: 2.7

- **Schmidt-Wolf** IGH, Rockstroh JK, Schlegel U, Pels H, Mey U, Strehl J, Weiss R, Huhn D. Treatment options of AIDS-related lymphoma. Expert Opinion on Pharmacotherapy 4(8):1331-1343 (2003)

IF: 2.9

- Ziske C, Mezger J, Jiménez C, Kleinschmidt R, Pels H, Schlegel U, **Schmidt-Wolf** IGH. High-dose chemotherapy with autologous peripheral blood stem cell support in an adult patient with a recurrent AFP-producing intracranial germinoma. German Medical Science Vol.1, Doc03, 20030701 (2003)

IF: 1.2

- **Schmidt-Wolf** IGH, Pels H (contributed equally), Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden

M, Egerer G, Bode U, Deckert M, Fimmers R, Helmstaedter C, Althaus A, Atasoy A, Klockgether T, Schlegel U. PCNSL: Results of a pilot / Phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21(24):4489-4495 (2003)

IF: 33.0

- Ziske C, Schlie C, Gorschlüter M, Glasmacher A, Mey U, Strehl J, Sauerbruch T, **Schmidt-Wolf** IGH. Prognostic value of CA19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Brit J Cancer 89(8):1413-1417 (2003)

IF: 5.8

- Gross C, **Schmidt-Wolf** IGH, Nagaraj S, Ellwart J, Kunz-Schughart L, Multhoff G. Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells. Cell Stress & Chaperones 8(4):348-360 (2003)

IF: 2.9

- Engelhart S, Hanfland J, Glasmacher A, Krizek L, **Schmidt-Wolf** IGH, Exner M. Impact of portable air filtration units on exposure of haematology-oncology patients to airborne Aspergillus fumigatus spores under field conditions. J Hospital Infection 54:300-304 (2003)

IF: 3.3

- Goldschmidt H, Sonneveld P, Cremer FW, van der Holt B, Westveer P, Breitkreutz I, Benner A, Glasmacher A, **Schmidt-Wolf** IGH, Martin H, Hoelzer D, Ho AD, Lokhorst H. The joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol 82 (10): 654-659 (2003)

IF: 2.9

- Sievers E, Albers P, **Schmidt-Wolf** IGH, Märten A. Telomerase pulsed dendritic cells for immunotherapy of renal cell carcinoma. J Urology 171:114-119 (2004)

IF: 5.9

- Schmidt T, Ziske C, Märten A, Endres S, Tiemann K, Schmitz V, Gorschlüter M, Schneider C, Sauerbruch T, **Schmidt-Wolf** IGH. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res 63:8962-8967 (2003)

IF: 9.7

- Schneider C, Schmidt T, Ziske C, Tiemann K, Lee KM, Uhlinsky V, Behrens P, Sauerbruch T, **Schmidt-Wolf** IGH, Mühlradt PF, Schmidt J, Märten A. Tumor suppression induced by macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. GUT 53:355-361 (2004)

IF: 19.8

- Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschlüter M, Mayr C, Ziske C, **Schmidt-Wolf** IGH. High-dose chemotherapy followed by ASCT as first-line therapy in aggressive NHL: a meta-analysis. Haematologica 88(11):1304-1315 (2003)

IF: 7.1

- Glasmacher A, Prentice A, Gorschlüter M, Engelhart S, Hahn C, Djulbegovic B, **Schmidt-Wolf** IGH. Itraconazole prevents invasive fungal infection in neutropenic patients treated for haematological malignancies: Evidence from a meta-analysis of 3597 patients. J Clin Oncol 21 (24) 4615-4626 (2003)

IF: 33.0

- Schakowski F, Buttgereit P, Mazur M, Märten A, Schöttker B, **Schmidt-Wolf** IGH. A novel non-viral method for transfection of primary leukemia cells and cell lines. Genetic Vaccines and Therapy, Vol. 2, <http://www.gvt-journal.com/content/2/1/1> (2004)

IF: 1.7

- Rabe C, Mey U, Paashaus M, Musch A, Tasci S, Glasmacher A, **Schmidt-Wolf** IGH, Sauerbruch T, Dumoulin FL. Outcome of patients with AML and pulmonary infiltrates requiring invasive mechanical ventilation – a retrospective analysis. J Crit Care 19 (1):29-35 (2004)

IF: 2.7

- Glasmacher A, Goldschmidt H, Mezger J, Haferlach T, **Schmidt-Wolf** IGH, Gieseler F. Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial. Haematologica 89(3):371-373 (2004)

IF: 7.1

- Nagaraj S, Ziske C, **Schmidt-Wolf** IGH. Dendritic cell, the immunotherapeutic cell. Indian J Med Res 119:133-138 (2004)

IF: 1.5

- Linnebank M, Schmidt S, Kölsch H, Linnebank A, Heun R, **Schmidt-Wolf** IGH, Glasmacher A, Fliessbach K,

Klockgether T, Schlegel U, Pels H. The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. *Brit J Cancer* 90:1969-1971 (2004)

IF: 5.8

- Ziske C, Nagaraj S, Märten A, Gorschlüter M, Strehl J, Sauerbruch T, Abraham NG, **Schmidt-Wolf** IGH. Retroviral interferon-alpha gene transfer combined with gemcitabine acts synergistically via cell cycle alteration in human pancreatic carcinoma cells implanted orthotopically in nude mice. *J Interferon Cytokine Res* 24(8):490-496 (2004)

IF: 2.0

- Schulz H, Pels H, **Schmidt-Wolf** IGH, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed CNS lymphomas with the anti-CD20 antibody rituximab. *Haematologica* 89(6): 753-754 (2004)

IF: 7.1

- Leo E, Scheuer L, **Schmidt-Wolf** IGH, Kerowgan M, Schmitt C, Leo A, Baumbach T, Kraemer A, Benner, Parwaresch R, Ho AD. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. *European J Hematol* 73:251-257 (2004)

IF: 2.2

- Schmidt S, Schneider T, **Schmidt-Wolf** IGH, Ko Y, Schlegel U, Klockgether T, Hertfelder HJ. C1-inhibitor activity and plasma concentrations in patients with monoclonal gammopathies: implications for treatment with recombinant interferon-beta 1b. *Mult Scler. Apr;10(2):243-244* (2004)

IF: 4.2

- von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, **Schmidt-Wolf** IGH, Marklein G, Schroeder S, Stuber F. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than CRP. *Europ J Clin Microbiol Infect Dis* 23(7):539-544 (2004)

IF: 2.8

- Nagaraj S, Ziske C, **Schmidt-Wolf** IGH. Human CIK cells have enhanced in vitro cytolytic activity via non-viral IL-2 gene transfer. *GVT* 2:12 www.gvt-journal.com/content/2/1/12 (2004)

IF: 1.7

- Mehrle S, Frank S, Schmidt J, **Schmidt-Wolf** IGH, Märten A. SAP and SLAM expression in anti-CD3 activated lymphocytes correlates with cytotoxic activity. Immunol Cell Biol 83:33-39 (2005)

IF: 3.7

- Ebert O, Wilbert D, Buttgereit P, Ziske C, Flieger D, Sauerbruch T, **Schmidt-Wolf** IGH. Effects of recombinant IL-2 and IL-12 in human B lymphoma cells on co-cultured lymphocytes. <http://www.gvt-journal.com/content/2/1/15>

IF: 1.7

- Pels H, Montesinos-Rongen M, Schaller C, Schlegel U, **Schmidt-Wolf** IGH, Wiestler OD, Deckert M. VH gene sequence analysis in PCNSL: Molecular phenotype correlated with clinical outcome. In Druck, J Neurol Sci

IF: 3.1

- Linnebank M, Pels H, Kleczar N, Farmand S, Fließbach K, Urbach H, Orlopp K, Klockgether T, **Schmidt-Wolf** IGH, Schlegel U. MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology 64:912-913 (2005)

IF: 8.8

- Bonn O, **Schmidt-Wolf** G, Risse R, Glasmacher A, Kleinschmidt R, **Schmidt-Wolf** IGH. Vindesine and etoposide: a practical and well tolerated therapy for elderly patients in reduced clinical condition with extensive stage small cell lung cancer (SCLC). (q:\PubSCLCMSM2.doc). Medical Science Monitor 11(2): PI19-21 (2005)

IF:1.9

- Fließbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, Juergens A, Glasmacher A, **Schmidt-Wolf** IGH, Klockgether T, Schlegel U. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 64(7):1184-1188 (2005)

IF: 8.8

- Erhardt M, Gorschlüter M, Sager J, Ziske C, Strehl J, von Lilienfeld-Toal M, **Schmidt-Wolf** IGH. Transfection of human monocyte-derived DC with CpG oligonucleotides. Immunology and Cell Biology 83, 278-285 (2005)

IF: 3.7

- von Lilienfeld-Toal M, Sievers E, Bodemüller V, Mihailescu C, Märten A, Gorschlüter M, **Schmidt-Wolf** IGH. Coculture with dendritic cells promotes proliferation of gamma/delta T cells. Immunol Lett 99(1):103-108 (2005)

IF: 3.3

- Gorschlüter M, Mey U, Strehl J, Ziske C, Schepke M, **Schmidt-Wolf** IGH, Sauerbruch T, Glasmacher A. Neutropenic enterocolitis in adults: Systematic analysis of evidence quality. Eur J Haematol 75(1):1-13 (2005)

IF: 2.2

- Schmidt J, Ryschich E, Sievers E, **Schmidt-Wolf** IGH, Büchler M, Märten A. Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo. Cancer 15;106(4):759-764 (2006)

IF: 5.7

- Palmedo H, Bender H, Urbach H, Schlegel U, **Schmidt-Wolf** IGH, Matthies A, Joe A, Bucerius J, Biersack HJ, Pels H. Primary diagnosis and therapeutic monitoring of primary central nervous system lymphoma with FDG-PET in immunocompetent patients: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging, Oct 12 (2005)

IF: 7.1

- Glasmacher A, von Lilienfeld-Toal M, Schulte S, Hahn C, **Schmidt-Wolf** IGH, Prentice A. An evidence-based evaluation of important aspects of empiric antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 11:17-23 (2005)

IF: 7.1

- Hombach A, Schlimper C, Sievers E, Frank S, Schild HH, Sauerbruch T, **Schmidt-Wolf** IGH, Abken H. A recombinant anti-CEA immunoreceptor with combined CD3zeta – CD28 signalling targets T cells from colorectal cancer patients against their tumor cells. GUT, Dec 2 (2005)

IF: 19.8

- Weiss R, Mitrou P, Arastéh K, Schuermann D, Seibt H, Ross B, Kubin T, Hentrich M, Duehrsen U, Pees H, Fleischer B, Heese C, **Schmidt-Wolf** IGH, Anagnostopoulos I, Huhn D. AIDS-related lymphoma (ARL): Simultaneous treatment with CHOP chemotherapy and with highly active antiretroviral therapy (HAART) is save and improves survival. Results of the German multicenter trial for the treatment of AIDS-related lymphomas. Cancer 106(7):1560-1568 (2006)

IF: 5.7

- Mey U, Orlopp KS, Flieger D, Strehl J, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U,

Neubauer A, Florschütz A, Hahn C, Glasmacher AG, **Schmidt-Wolf** IGH. DHAP in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive NHL. *Cancer Investigation* 24 (6):593-600 (2006)

IF: 2.4

- **Schmidt-Wolf** IGH, Glasmacher A, Hahn-Ast C, Jüttner A, Schnurr T, Cremer F, Moehler T, Goldschmidt H, Buser B, Schubert R, Schwanitz G. Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance. *Cancer Genetics Cytogenetics* 167:20-25 (2006)

IF: 1.9

- Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, **Schmidt-Wolf** IGH, Gorschlüter M. A systematic review of phase II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. *Brit J Haematol* 132(5):584-593 (2006)

IF: 5.5

- Gonzalez-Carmona MA, Märten A, Hoffmann P, Schneider C, Sievers E, **Schmidt-Wolf** IGH, Sauerbruch T, Caselmann WH. Patient-derived DCs transduced with an AFP-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. *Liver International*, 26:369-379 (2006)

IF: 5.2

- Gorschlüter M, Mey U, Strehl J, Schmitz V, Wardelmann E, Ziske C, **Schmidt-Wolf** IGH, Glasmacher A., v. Lilienfeld-Toal, M. Invasive fungal infections in neutropenic enterocolitis: A systematic analysis of pathogens, incidence, treatment and mortality in adult patients. *BMC Infect Dis.* 2006 Feb 26;6:35. doi: 10.1186/1471-2334-6-35. PMID: 16504141; PMCID: PMC1448178.

IF: 2.7

- Orlopp K, **Schmidt-Wolf** IGH, Urbach H, Schlegel U. Akute zentralnervöse Symptome bei onkologischen Patienten. *Der Internist* 46(1):19-29 (2005)

IF: 0.4

- Gorschlüter M, Mey U, Glasmacher A, Schwerdtfeger R, **Schmidt-Wolf** IGH. Acute myeloid leukemia with near-triploid karyotype and extramedullary involvement of mediastinum. *Bone Marrow Transplant* 36(12):1107 (2005)

IF: 4.7

- Lamberti C, Di Blasi K, Archut D, Fimmers R, Mathiak M, Bollmann M, Vogel J, Kindermann D, Mezger J, **Schmidt-Wolf** IGH, Sauerbruch T. Population-Based Registration of Unselected Colorectal Cancer Patients: Five-Year Survival in the Region of Bonn/Rhine-Sieg, Germany. *Z Gastroenterol* 43:149-154 (2005)

IF: 1.3

- Link BC, Ziske CG, Schepke M, Schmidt-Wolf IGH, Sauerbruch T. Total ascitic fluid leukocyte count for reliable exclusion of spontaneous bacterial peritonitis in patients with ascites. *Eur J Gastroenterol Hepatol* 18(2):181-186 (2006)

IF: 2.3

- Lamberti C, Lundin S, Bogdanow M, Gorschlüter M, **Schmidt-Wolf** IGH, Sauerbruch T. Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials. *DMW* 131 (10):485-490 (2006)

IF: 0.6

- von Lilienfeld-Toal M, Nattermann J, Feldmann G, Sievers E, Frank S, Strehl J, **Schmidt-Wolf** IGH. Activated gamma delta T cells express the natural cytotoxicity receptor NKp44 and show cytotoxic activity against myeloma cells. *Clinical Exper Immunol* 144(3):528-533 (2006)

IF: 3.5

- Märten A, Sievers E, Albers P, Müller S, Franchy C, von Ruecker A, Strunk H, Schild HH, Schmiedel A, Sommer T, Sauerbruch T, **Schmidt-Wolf** IGH. Telomerase-pulsed dendritic cells: Preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. *German Medical Science* 4: Doc02 (2006)

IF: 1.2

- Nagaraj S, Ziske C, Strehl J, Messmer D, Sauerbruch T, **Schmidt-Wolf** IGH. Dendritic cells pulsed with alpha-galactosylceramide induce antitumor immunity against pancreatic cancer in vivo. *International Immunology* 18(8):1279-1283 (2006)

IF: 3.5

- Telusma G, Datta S, Mihajlov I, Ma W, Li J, Yang H, Newman W, Messmer BT, Minev B, **Schmidt-Wolf** IGH, Tracey KJ, Chiorazzi N and Messmer D. Dendritic cell activating peptides induce distinct cytokine profiles. *Int Immunol* 18(11): 1563-1573 (2006)

IF: 3.5

- Geiser F, Hahn C, Conrad R, Liedtke R, Sauerbruch T, **Schmidt-Wolf** I, Glasmacher A. Interaction of psychosocial factors and the effect of epoietin alfa treatment in cancer patients on hemoglobin and fatigue. Supportive Care in Cancer 15(3):273-8 (2007)

IF: 2.6

- Mey U, Olivieri A, Orlopp K, Rabe C, Strehl J, Gorschlüter M, Hensel M, Flieger D, Glasmacher A, **Schmidt-Wolf** IGH. DHAP in combination with rituximab versus DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leukemia & Lymphoma 47(12):2558-2566 (2006)

IF: 3.0

- Messmer D, Hatsukari I, Hitosugi N, **Schmidt-Wolf** IGH, Singhal PC. Morphine reciprocally regulates IL-10 and IL-12 production by monocyte-derived human DC and enhances T cell activation. Mol Med 12(11-12):284-290 (2006)

IF: 4.1

- Erhardt M, **Schmidt-Wolf** IGH, Sievers E, Frank S, Strehl J, v. Lilienfeld-Toal M, Gorschlüter M. Antitumoral capabilities of effector cells after interferon- α or CpG-motif treatment of cocultured dendritic cells. Arch Immunol Ther Exp 54 (6): 403-409 (2006)

IF: 3.2

- Lamberti C, Mangold E, Pagenstecher C, Jungck M, Schwering D, Bollmann M, Vogel J, Kindermann D, Nikorowitsch R, Friedrichs N, Schneider B, Houshdaran F, Schmidt-Wolf IGH, Friedl W, Propping P, Sauerbruch T, Büttner R, Mathiak M. Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany. Digestion. 2006;74(1):58-67.

IF: 2.7

- Schakowski F, Gorschlüter M, Buttgereit P, Märten A, von-Lilienfeld-Toal M, Junghans C, Schroff M, König-Meridiz SA, Ziske C, Strehl J, Sauerbruch T, Wittig B, **Schmidt-Wolf** IGH. Minimal size MIDGE vectors improve transgene expression in vivo. In Vivo 21:17-24 (2007)

IF: 1.5

- Sievers E, Haferkamp A, Dreimüller P, **Schmidt-Wolf** IGH, Schmidt J, Märten A. Characterization of primary renal carcinoma cultures. Urologia Internationalis, in Druck

IF: 1.7

- Mey U, Maier A, **Schmidt-Wolf** IGH, Ziske C, Forstbauer H, Banat GA, Reber M, Strehl J, Gorschlüter M. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Supportive Care in Cancer, online, 2007 Jan 19

IF: 2.6

- Courts C, Montesinos-Rongen M, Martin-Subero JI, Brunn A, Bechtel D, Zühlke-Jenisch R, Pels H, Jürgens A, Schlegel U, **Schmidt-Wolf** IGH, Schaller C, Reifenberger G, Sabel M, Warnecke-Eberz U, Wiestler OD, Küppers R, Siebert R, Deckert M. Transcriptional profiling of the NF- κ B pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression and unfavorable prognosis. J Neuropathol Exp Neurol 66(3):230-237 (2007)

IF: 2.9

- Gorschlüter M, Glasmacher A, Sarazin S, Hackbarth F, Hoebert E, Orlopp K, **Schmidt-Wolf** IGH, Mey U. CD4+ T lymphocyte counts after autologous transplantation in multiple myeloma. A retrospective study. Leukemia and Lymphoma, 48(3):506-512 (2007)

IF: 3.0

- Hedde JP, Neuhaus T, Schüller H, Metzler U, **Schmidt-Wolf** IGH, Kleinschmidt R, Loosem C, Lange O, Grohé C, Stier S, Ko YD. A phase I/II Trial of Topotecan and Radiation Therapy for Brain Metastases in Patients with Solid Tumors. Int J Radiat Oncol Biol Phys. 2007 Mar 20

IF: 5.9

- Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutherlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, **Schmidt-Wolf** IGH, Roll L, Doerken B, Riess H. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial. JAMA 297 (3): 267-277, 2007.

IF: 45.5

- Lorch A, Rick O, Hartmann JT, Kollmansberger C, Metzner B, **Schmidt-Wolf** IGH, Glasmacher A, Berdel WE, Schirren R, Beyer J, Bokemeyer C. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: A prospective randomized multicenter

trial of the German Testicular Cancer Study Group. JCO 25(19):2778-2784, 2007.

IF: 33.0

- Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, Mc Dermott D, Bodrogi I, Kovacevic Z, Lesovoy V, **Schmidt-Wolf** IGH, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer R. Temsirolimus, Interferon alfa, or both for Advanced Renal-Cell Carcinoma. NEJM (The New England Journal of Medicine) 356(22):2271-2281 (2007)

IF: 74.7

- Breitkreutz I, Lokhorst HM, Raab MS, van der Holt BV, Cremer FW, Herrmann D, Glasmacher A, **Schmidt-Wolf** IGH, Blau IW, Martin H, Salwender H, Hänel A, Sonneveld P, Goldschmidt H. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide on peripheral blood stem cell collection yield. Leukemia 1-6, 2007 Mar 22

IF: 8.7

- Flieger D, Varvenne M, Kleinschmidt R, **Schmidt-Wolf** IGH. Influence of immunomodulatory drugs on the cytotoxicity induced by monoclonal antibody 17-1A and interleukin-2. Cellular Immunol 246(1):26-33, 2007.

IF: 4.1

- Mey UJM, Jha V, Strehl JW, Gorschlüter M, Rabe C, Hoebert E, Popp H, **Schmidt-Wolf** IGH. High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma. Ger Med Sci. 2007;5:Doc02. Published 2007 Jun 19.

IF: 1.2

- Gütgemann S, Frank S, Strehl J, **Schmidt-Wolf** IGH. Cytokine-induced killer cells are type II natural killer T cells. Ger Med Sci. 2007;5:Doc07. Published 2007 Sep 10.

IF: 1.2

- Ziske C, Tiemann K, Schmidt T, Nagaraj S, Märten A, Schmitz V, Clarenbach R, Sauerbruch T, **Schmidt-Wolf** IGH. Real-time compound imaging allows percutaneous initiation and surveillance in an orthotopic murine pancreatic cancer model. Pancreas 2008 Mar;36(2):146-52.

IF: 2.9

- Shimomura A, von Lilienfeld-Toal M, Balta Z, Schroers E, **Schmidt-Wolf** IGH, Büttner R, von Rücker A, Gütgemann I. Lack of Surface and Cytoplasmic Immunoglobulin Light Chains in a HIV-related Burkitt Lymphoma. Ann Hematol,

in Druck

IF: 2.9

- Lokhorst HM, **Schmidt-Wolf** IGH, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos G, Croockewit A, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender H, van Oers MH, Schaafsma M, Naumann R, Sinnige H, Blau W, Verhoef G, de Weerd O, Wijermans P, Wittebol S, Duehrsen U, Vellenga E, Goldschmidt H; for Dutch-Belgian HOVON and German GMMG. Thalidomide in induction treatment increases the very good partial response (VGPR) rate before and after high-dose therapy in previously untreated multiple myeloma. *Haematologica* 93(1):124-127 (2008)

IF: 7.1

- Glas M, Hennemann B, Hirschmann B, Marienhagen J, **Schmidt-Wolf** I, Herrlinger U, Bogdahn U, Hau P. Complete response after treatment with a somatostatin analogue in a patient with recurrent medulloblastoma. *Acta Oncologica* 47(3):479-804 (2008)

IF: 3.7

- Sievers E, Neuberg J, Starkmuth M, Frank S, Strehl J, **Schmidt-Wolf** IGH. Cytotoxicity of a CD94-enriched fraction from cytokine-induced killer (CIK) cells against tumor cells. *Current Trends in Immunology*, 10:41-48 (2009)

IF: 10.7

- Gütgemann I, Stevens K, Loftus D, Schmidt-Wolf IGH, George TI. VEGF and Osteosclerosis in POEMS Syndrome. *Annals Hematol* 87:243-245 (2008)

IF: 2.9

- González-Carmona MA, Lukacs-Kornek V, Timmermann A, Shabani S, Kornek M, Vogt A, Yildiz Y, Sievers E, **Schmidt-Wolf** IGH, Caselmann W, Sauerbruch T, Schmitz V. CD40L-expressing DCs induce regression of HCC by activating innate and acquired immunity in vivo. *Hepatology* 48 (1):157-168 (2008)

IF: 14.7

- Nagaraj S, Neumann J, Winzen B, Frank S, Ziske C, Sievers E, Koch N, **Schmidt-Wolf** IGH. Pancreas carcinoma antigen fused to invariant chain elicits T cell response and tumor growth inhibition. *Pancreas* 37(3):321-327, 2008

IF: 2.9

- Gorschlüter M, Schmitz V, Mey U, Hahn-Ast C, **Schmidt-Wolf** IGH, Sauerbruch T. Endoscopy in patients with acute leukaemia after intensive chemotherapy. *Leukemia Res*

32:1510-1517 (2008)

IF: 2.2

- Kim Y, Strehl J, Gorschlüter M, Ziske C, Schmidt-Wolf IGH. Prevention of lethal tumor growth and generation of long-lasting immunity in vivo using CD137L and interleukin-12 gene transfer. *In Vivo* 22:337-344 (2008)

IF: 1.5

- Gressner O, Popp H, Fmeyer U, Strehl J, Sauerbruch T, **Schmidt-Wolf I**, Gorschlüter M. Long-term survival of a patient with Small Cell Lung Cancer after 9 treatments with different chemotherapy regimens and radiation: a Case Report. *Onkologie* 31:469-472 (2008)

IF: 1.5

- [Pels H](#), [Juergens A](#), [Glasmacher A](#), [Schulz H](#), [Engert A](#), [Linnebank M](#), [Schackert G](#), [Reichmann H](#), [Kroschinsky F](#), [Vogt-Schaden M](#), [Egerer G](#), [Bode U](#), [Schaller C](#), [Lamprecht M](#), [Hau P](#), [Deckert M](#), [Fimmers R](#), [Bangard C](#), [Schmidt-Wolf IGH](#), [Schlegel U](#). Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. *J Neurooncol.* 2009 Feb;91(3):299-305.

IF: 3.3

- [Linnebank M](#), [Moskau S](#), [Jurgens A](#), [Simon M](#), [Semmler A](#), [Orlopp K](#), [Glasmacher A](#), [Bargart C](#), [Vogt-Schaden M](#), [Urbach H](#), [Schmidt-Wolf IG](#), [Pels H](#), [Schlegel U](#). Association of genetic variants of methionine metabolism with MTX-induced CNS white matter changes in patients with primary central nervous system lymphoma. *Neuro Oncol.* 2008 Sep 22.

IF: 10.2

- Schmidt M, Sievers E, Endo T, Lu D, Carson D, Schmidt-Wolf IGH. Targeting Wnt pathway in lymphoma and myeloma cells. *Brit J Haematol.* 2009 Mar;144(5):796-8.

IF: 5.5

- **Linke A**, **Sievers E**, **Gonzalez-CarmonaM**, **Ziske C**, **Messmer D**, **Schmitz V**, **Sauerbruch T**, **Brossart P**, **Schmidt-Wolf IGH**. Enhanced inhibition of tumor growth with depletion of CD25 regulatory cells and intratumoral immunization with tumor RNA-pulsed dendritic cells in a C57Bl/6 pancreatic tumor model. *Pancreas* 38 (5):602-604 (2009)

IF: 2.9

- Kraemer A, Hauser S, Kim Y, Gorschlüter M, Müller SC, Brossart P, **Schmidt-Wolf I**. Phase I trial of metastatic renal cell carcinoma. with oral capecitabine and

thalidomide. GMS Vol 7, 2009 (online)

IF: 1.2

- Ziske C, Etzrodt PE, Eliu AS, Gorschlüter M, Strehl J, Flieger D, Messmer D, Schmitz V, Gonzalez-Carmona MA, Sievers E, Brossart P, Sauerbruch T, **Schmidt-Wolf** IGH. Increase of In Vivo Antitumoral Activity by CD40L (CD154) Gene Transfer Into Pancreatic Tumor Cell-Dendritic Cell Hybrids. Pancreas. 2009 Oct;38(7):758-65.

IF: 2.9

- Juergens A, Pels H, Rogowski S, Fließbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, **Schmidt-Wolf** IGH, Schlegel U. Long-term survival with favorable cognitive outcome after chemotherapy in Primary Central Nervous System Lymphoma. Ann Neurol. 2010;67(2):182-189. doi:10.1002/ana.21824

IF: 9.0

- Advani A, Patel H, Boni J, Coiffier B, Czuczman M, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, **Schmidt-Wolf** IGH, Schuler M, Sierra J, Smith M, Verhoef G, Winter J, Shapiro M, Fayad L. A Phase 1 Study of Inotuzumab Ozogamicin (CMC-544) as Treatment for B-Cell Non-Hodgkin's Lymphoma: JCO 28(12):2085-93 (2010).

IF: 33.0

- Kim Y, Strehl J, Sievers E, Gorschlüter M, Brossart P, **Schmidt-Wolf** IGH. CD40L transfected myeloma cells transfer prolonged immunity in vivo. In Vivo 24:45-48 (2010)

IF: 1.5

- Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, **Schmidt-Wolf** IGH, Kipps TJ, Carson DA. Ethacrynic acid exhibits selective cytotoxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS one, 2009 Dec 14;4(12):e8294

IF: 2.7

- von Lilienfeld-Toal M, Frank S, Leyendecker C, Feyler S, Jarmin S, Morgan R, Glasmacher A, Märten A, **Schmidt-Wolf** IGH, Brossart P, Cook G. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. CII 2010 Jun;59(6):829-39

IF: 5.4

- Pels H, Juergens A, Schirgens I, Glasmacher A, Schulz H, Engert A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Deckert M, Fimmers R, Urbach H, **Schmidt-Wolf** IGH, Schlegel U. Early complete response during chemotherapy predicts favourable outcome in patients with primary CNS lymphoma. *Neurooncology*, 2010 Jul;12(7):720-4, Epub 2010 Feb 16

IF: 10.2

- Kraemer M, Hauser S, **Schmidt-Wolf** I. Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells. *Anticancer Res.* 2010 Jun;30(6):2081-6.

IF: 2.0

- Simons S, Ringsdorf S, Braun M, Mey UJM, Ko YD, Kuhn W, **Schmidt-Wolf** IGH, Schwindt PF, Jaehde U. Enhancing adherence to capecitabine chemotherapy by means of pharmaceutical care: a prospective observational cohort study, *Supportive Care in Cancer*. IF(2010):2,1 (2011) 19:1009-1018, published online 16 June 2010

IF: 2.6

- Busert B, Schwanitz G, Schubert R, Gamberdinger U, **Schmidt-Wolf** IGH. Characterization of the karyotype in patients with multiple myeloma by the combination of karyotype analysis, FISH and CGH. *Int J Human Genetics*, 2011. IF(2010):0,2, (2010)10(4):217-222

IF: 0.3

- Sievers E, Neuberg J, Starkmuth M, Frank S, Strehl J, **Schmidt-Wolf** IGH. Cytotoxicity of a CD94-enriched fraction from cytokine-induced killer (CIK) cells against tumor cells. *Current Trends in Immunology*, 10:41-48 (2009)

IF: 0.6

- Kim Y, Strehl J, Sievers E, Gorschlüter M, Brossart P, **Schmidt-Wolf** IGH. CD40L transfected myeloma cells transfer prolonged immunity in vivo. *In Vivo* 24:45-48 (2010)

IF: 1.5

- Gröschel S, Lugthart S, Schlenk RF, Valk PJM, Eiwen K, Goudswaard C, van Putten WJL, Kayser S, Verdonck L, Lübbert M, Ossenkoppele GJ, Germing U, **Schmidt-Wolf** IGH, Schlegelberger B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner K, Delwel R. High *EVI1* Expression Predicts Outcome in Younger Adult Patients with Acute Myeloid Leukemia and Is Associated with Distinct Cytogenetic Abnormalities. *J Clin Oncol.* 2010 Apr

20;28(12):2101-7.

IF: 33.0

- Hontscha C, Zhou H, Negrin R, **Schmidt-Wolf** IGH. Clinical trials on CIK cells: First report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol, 2011 Feb;137 (2):305-310.

IF: 3.7

- Schmidt M, Sievers E, Endo T, Lu D, Glasmacher A, Brossart P, Carson D, **Schmidt-Wolf** IGH Increased efficacy of lenalidomide and thalidomide by addition of PO targeting the Wnt pathway. In Vivo. 2011;25(3):325-333.

IF: 1.5

- Kim Y, Alpmann P, Blaum-Feder S, Krämer S, Endo T, Lu D, Carson D, **Schmidt-Wolf** IG. Increased in vivo efficacy of lenalidomide by addition of piroctone olamine. In Vivo. 2011 Jan-Feb;25(1):99-103. PMID: 21282741.

IF: 2.2

- Nowak M, Arredouani M, Tun-Kyi A, **Schmidt-Wolf** IGH, Sanda M, Balk S, Exley M. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide. PLoS One. 2010 Jun 25;5(6):e11311. IF(2010): 4,4
- Gaidzik V, Bullinger L, Schlenk R, Zimmermann A, Röck J, Paschka P, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Späth D, Germing U, **Schmidt-Wolf** IGH, Götze K, Nachbaur D, Pfreundschuh M, Horst H, Döhner H, Döhner K. *RUNX1* mutations in acute myeloid leukemia – a distinct biological subgroup associated with inferior outcome. Results of the AML Study Group (AMLSG). JCO, Volume 29 (2011).

IF: 33.0

- Schmidt M, Sievers E, Endo T, Lu D, Glasmacher A, Brossart P, Carson D, **Schmidt-Wolf** IGH Increased efficacy of lenalidomide and thalidomide by addition of griseofulvin targeting the Wnt pathway. Leuk Res. 35(8):1070-3.

IF: 2.3

- Li Y, Wu Y, **Schmidt-Wolf** IGH, Huang S, Guo H, Fang J, Wei J, Huang K, Zhou D. Optimized protocols for generation of cord blood derived cytokine-induced killer / natural killer cells. Anticancer Res. Sept 30(9):3493-3499 (2010).

IF: 2.0

- Kim Y, Reifenberger G, Lu D, Endo T, Carson DA, Gast SM,

Meschenmoser K, Nowak M, **Schmidt-Wolf** IGH. Influencing the Wnt Signaling Pathway in Multiple Myeloma. *Anticancer Res*, IF(2010):1,7, 2011; Volume 31; Issue 2, Pages 725-730

IF: 2.0

- Schmidt M, Kim Y, Gast S-M, Endo T, Lu D, Carson D, Kipps T, **Schmidt-Wolf** IGH Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid., *In Vivo*. IF(2010):1,2 , 2011 May- June; 25 (3):325-33

IF: 1.1

- Patrij K, Reiser M, Wätzel L, Pels H, Kowoll A, Herrlinger U, Engert A, Linnebank M, Schackert G, Vogt-Schaden M, Egerer G, Lamprecht M, Batchelor TT, Schlegel U, **Schmidt-Wolf** IG; International Primary CNS Lymphoma Collaborative Group (IPCG). Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. *Ger Med Sci*. 2011;9:Doc11. doi: 10.3205/000134. Epub 2011 May 2. PMID: 21698087; PMCID: PMC3118693.

IF: 1.2

- Thanandrarajan S, Nowak M, Abken H, **Schmidt-Wolf** IGH. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: More than one plus one? *Leukemia Res*, <http://dx.doi.org/10.1016/j.leukres.2011.05.005>. 2011 Sept;35 (9): 1136-42

IF: 2.2

- Schöttker B, Märten A, Kenn C, Ziske C, Renoth S, Buttgereit P, Schakowski F, Gorschlüter M, **Schmidt-Wolf** IGH. Dendritic Cells Enhance the Anti-Leukemic Activity of Cytokine-Induced Killer Cells against Allogeneic Acute Myelogenous Leukaemia Cells. *GMS* unter <http://www.egms.de/en/journals/gms/2011-9/000141.shtml>, August 4;2011

IF: 1.2

- Auel B, Goldschmidt H, Geer T, Moehler TM, Platzbecker U, Naumann R, Blau I, Hänel M, Knauf W, Nüchel H, Salwender HJ, Scheid C, Weisel K, Gorschlüter M, Glasmacher A, **Schmidt-Wolf** IGH, for the German Refractory Myeloma Study Group. Treatment with thalidomide and cyclophosphamide (TCID) is superior to vincristine (VID) and to vinorelbine (VRID) regimens in patients with refractory or recurrent multiple myeloma. *Ind J Hematol*, DOI 10.1007/s12288-011-0133-1; 2012

IF 1.6

- Kim Y, Schmidt M, Endo T, Lu D, Carson D, **Schmidt-Wolf** IG. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model. In Vivo. 2011;25(6):887-893. PMID: 22021681.

IF: 1.5

- Futalan D, Huang CT, **Schmidt-Wolf** I, Larsson M, Messmer D. Effect on oxygen levels on the physiology of dendritic cells: Implications for adoptive cell therapy. Molecular Medicine, IF(2010):5,9, 2011; Sept-Oct 17 (9-10): 910-6

IF: 4.1

- Hendrayana T, Kurth V, Krolop L, Kenny P, Hilger RA, **Schmidt-Wolf** IGH, Ko YD, Jaehde U. Variability in fluorouracil exposure during continuous intravenous infusion. International Journal of Clinical Pharmacology and Therapeutics, IF(2010):1,2, 2012 Jan 50 (1):82-4

IF: 0.9

- Nowak M, **Schmidt-Wolf** IGH. Natural Killer T Cells Subsets in Cancer, Functional Defects in Prostate Cancer and Implications for Immunotherapy. Cancers, 2011; 3(3):3661-3675

IF: 6.5

- Schwamborn K, Gorschlüter M, Glasmacher A, **Schmidt-Wolf**, Ingo GH for the German Refractory Myeloma Study Group. Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma. GMS, September 27;2011

IF: 1.2

- Stuplich M, Mayer K, Kim Y, et al. Richter syndrome and brain involvement: low-grade lymphoma relapsing as cerebral high-grade lymphoma. Acta Haematol. 2012;127(2):93-95.

IF: 1.2

- Thanendrarajan S, Kim Y, **Schmidt-Wolf** IGH. Understanding and targeting the Wnt/i-catenin signaling pathway in chronic leukemia. Leukemia Research and Treatment, vol. 2011, <http://www.hindawi.com/journals/lrt/2011/329572/> (IF-),14 Oct 2011: Pages1-7

IF: 0

- Kim Y, Thanendrarajan S, **Schmidt-Wolf** IGH. Wnt/beta-Catenin: a new therapeutic Approach to Acute Myeloid

Leukemia? Leukemia Research and Treatment, vol. 2011, <http://www.hindawi.com/journals/lrt/2011/428960/> (IF-); 21 Oct 2011: Pages1-4

IF: 2.3

- Schlimper C, Hombach AA, Abken H, Schmidt-Wolf IG. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol. 2012;2012:238924. doi: 10.1155/2012/238924. Epub 2012 Mar 19. PMID: 22481963; PMCID: PMC3310246.

IF: 3.6

- Kunzmann V, Smetak M, Kimmel B, Weigang-Koehler K, Goebeler M, Birkmann J, Becker J, **Schmidt-Wolf** IGH, Einsele H, Wilhelm M. Phase II Trial of Zoledronic Acid plus Interleukin-2 in Patients with Solid and Hematological Malignancies. JIT (IF3,8), 2012 Feb;35(2):205-13

IF: 4.1

- Koppitz H, Rockstroh JK, Schüller H, Standop J, Skowasch D, Müller-Hermelink HK, **Schmidt-Wolf** IGH. Current status of classification and multimodality treatment of malignant thymoma: An update. Cancer Treatment Reviews, <http://dx.doi.org/10.1016/j.ctrv.2011.11.010> (IF7,6),online 13 January 2012

IF: 8.9

- Linnebank M, Moskau S, Kowoll A, Semmler A, Bangard C, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, **Schmidt-Wolf** IG, Pels H, Schlegel U. Association of transcobalamin c. 776C>G with overall survival in patients with primary central nervous system lymphoma. Br J Cancer. 2012 Nov 20;107(11):1840-3. doi: 10.1038/bjc.2012.476. 2012. (IF5,0)

IF: 5.8

- Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Hose D, Schmitt S, el Jarari L, Salwender H, Blau IW, Pfreundschuh M, Weisel K, Duehrsen U, Lindemann W, Teschendorf C, Martin H, Scheid C, Haenel M, Derigs HG, Graeven U, **Schmidt-Wolf** IGH, Peter N, Wattad M, Schubert J, Hoffmann M, Goerner M, Tischler J, Kaufmann M, van de Velde H, Raab MS, Sonneveld P, Goldschmidt H. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in Multiple Myeloma patients with deletion 17p – a Subgroup Analysis of the HOVON/GMMG-HD4 Trial. Blood, (IF 10,6), January 26;2012 Vol 119; no 4:940-948 IF: 17.5
- Jäckel C, Meschenmoser K, Kim Y, Weiher, **Schmidt-Wolf**

IGH. Efficacy of a proapoptotic peptide in breast cancer cells. *In Vivo* 2012 May-Jun;26(3):419-26.

IF: 1.5

- Kim Y, Gast SM, Endo T, Lu D, Carson D, **Schmidt-Wolf** IGH. *In vivo* efficacy of the diuretic agent ethacrynic acid against multiple myeloma. *Leukemia Research*. 36(5):598-600 (2012). IF 2,6

IF: 2.2

- Thanendrarajan S, Kim Y, **Schmidt-Wolf** IGH. New adoptive immunotherapy strategy for solid tumors with CIK cells. *Expert Opin Biol Ther*. 2012 May;12(5):565-72. IF 3,3

IF: 3.2

- Sonneveld P, **Schmidt-Wolf** IGH, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel K, Wittebol S, Bos GMJ, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van de Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk Kooy M, Duhrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt H. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase 3 HOVON-65/GMMG-HD4 trial. *J Clin Oncol*. 2012 Aug 20;30(24):2946-55. IF(2010):19,0

IF: 33.0

- Gröschel S, Schlenk R, Engelmann J, Rockova V, Teleanu V, Kühn M, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, **Schmidt-Wolf** IGH, Beverloo B, Schlegelberger B, Krauter J, Ganser A, Valk P, Löwenberg B, Döhner K, Döhner H, Delwel R. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian AMLSG and Dutch-Belgian HOVON groups. *J Clin Oncol* 31(1):95-103 (2013);

IF: 33.0

- Yordanova A, Hose D, Neben K, Witzens-Harig M, Klein B, Moehler T, Goldschmidt H, **Schmidt-Wolf** IGH. Efficacy of sorafenib in patients with refractory or recurrent multiple myeloma. *Hematological Oncology, Hematol Oncol*. 2013 Mar 15. doi: 10.1002/hon.2043. [Epub ahead of print].

IF: 2.8

- McClanahan F, Hielscher T, Rieger M, Hensel M, Bentz M, **Schmidt-Wolf** I, Käbisch A, Salwender H, Dürk H, Staiger H, Mandel T, Neben K, Hillengass J, Ho AD, Witzens-Harig M. Final results of a prospective, multicentre, randomized

trial comparing 1, 3 or 6 infusions of Rituximab combined with 6 cycles of CHOP chemotherapy in untreated patients with advanced follicular lymphoma (HD2000 trial). *Am J Hematol* 2012 Oct;87(10):E68-71.

IF: 7.0

- Chmielewski M, Hahn O, Nowak M, **Schmidt-Wolf** IGH, Hombach AA, Abken H. Regression of pancreatic carcinoma without inducing auto-immune colitis by T cell therapy targeting carcinoembryonic antigen. *Gastroenterology*. 2012 Oct;143(4):1095-107.

IF: 17.4

- Low HZ, Kramer D, **Schmidt-Wolf** IGH, Illges H. Shedding of CD21 is enhanced and correlates with attenuated surface expression of CD21 in CLL but not in MM. *International Journal of Hematology*, 2012 Sep;96(3):350-6.

IF: 2.2

- Jäkel C, Hauser S, Rogenhofer S, Müller SC, Brossart P, **Schmidt-Wolf** IGH. Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. *Clinical and Developmental Immunology* vol. 2012, Article ID 473245, 7 pages, 2012. doi:10.1155/2012/473245.

IF: 3.6

- Khristi J, Gütgemann I, **Schmidt-Wolf** I. Composite lymphoma: case reports and review of the literature. *Annals Hematol*, 2013 Apr 5. [Epub ahead of print].

IF: 2.9

- Koller CM, Kim Y, **Schmidt-Wolf** IGH. Targeting renal cancer with a combination of WNT inhibitors and a bi-functional peptide. *Anticancer Res*. 2013 Jun;33(6):2435-40.

IF: 2.0

- Meschenmoser K, Messmer D, **Schmidt-Wolf** IGH. PTargeting cancer with a bi-functional peptide: In vitro and in vivo results. *In Vivo*, 2013 Jul-Aug;27(4):431-42.

IF: 1.5

- Mansoor SA, Ziske C, **Schmidt-Wolf** IGH. Primary small-cell carcinoma of the esophagus: Multivariate analysis and review of the literature. *Ger Med Sci*. 2013 Aug 23;11:Doc12. doi: 10.3205/000180.

IF: 1.2

- Nowak M, Krämer B, Haupt M, Papapanou P, Kebschull J, Hoffmann P, **Schmidt-Wolf** IGH, Jepsen S, Brossart P,

Perner S, Kebschull M. Activation of Invariant Natural Killer T cells in Periodontitis Lesions. J Immunol 2013; 190(5): 2282-91 (2013)

IF: 4.9

- Vogt A, Sievers E, Lukacs-Kornek V, Decker G, Raskopf E, Meumann N, Büning H, Sauerbruch T, Strassburg CP, **Schmidt-Wolf** IGH, Gonzalez-Carmona MA. Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 *in vivo*. 2013, Liver Int. 2014 Mar;34(3):447-61.

IF: 5.2

- Schmeel LC, Schmeel FC, Kim Y, Endo T, Lu D, **Schmidt-Wolf** IGH. Taregting the Wnt/beta-catenin pathway in multiple myeloma. Anticancer Res. 2013 Nov;33(11):4719-26.

IF: 2.0

- Scheid C, Sonneveld P, **Schmidt-Wolf** IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585. Epub 2013 Aug 30. PMID: 23996482; PMCID: PMC4007933..

IF: 7.1

- Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel M, Kaiser U, Niederle N, Link H, Brugger W, Barth J, Welslau M, Banat A, Hinke A, Knauf W, Kofahl-Krause D, Weidmann E, Klein M, Baldus M, Sandherr M, Aulmann C, Schlimok G, Baldus M, Böck HP, Balló H, Balser C, Weidenbach F, Behringer D, Krüger S, Mitrou PS, Bojko P, Abenhardt W, Breuer F, Brudler O, Brugger W, Burchardt A, Blau W, Banat A, Chow K, Cordes HJ, Clemens M, Mahlberg R, Dürk H, Eckart M, Eggert J, Fiechtner H, Fuxius S, Görner M, Just M, Schäfer E, Graubner M, Günther G, Hahn L, Hecker R, Heil G, Herrmann O, Hochdörfer S, Hoffmann T,

Hünermund K, Immenschuh P, Burk M, Josten K, Kaiser U, Heide T, Katz F, Klein S, Knauf W, Tesch H, Kobbe G, Zohren F, Haas R, Koch M, Rauh J, Köchling G, Kofahl-Krause D, Ganser A, Kojouharoff G, Dingeldey G, Koniczek S, Link H, Kirsch J, Losem C, Maschmeyer G, Rothmann F, Matzdorff A, Mittermüller J, Müller S, Hahn M, Müller L, Müller-Hagen S, Neise M, Schalk K, Neuhaus T, Hens K, Niederle N, Heider A, Kloster G, Nowak H, Prümmer O, Reeb M, Hansen R, Rohrberg R, Hurtz HJ, Fritze D, Rost A, Brecht A, Kayser R, Bernhard H, Sandherr M, Perker M, Schauer M, Schlag R, Schliesser G, Käbisch A, Weber C, Schmidt UM, **Schmidt-Wolf** I, Brossart P, Schneider J, Schröder J, Schroeder M, Schütte HJ, Artmann KD, Schwaner I, Seipelt G, Koch U, Selbach J, Anhuf J, Söling U, Stauch M, Thiel E, Hofmann WK, Fischer L, Tischbirek K, von Grünhagen U, Wagner H, Wilke J, Wattad M, Reimer P, Weide R, Heymanns J, Weidmann E, Jäger E, Weiss J, Welslau M, Klausmann M, Wittmann G, Zimmer J. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet*. 2013 Apr 6;381(9873):1203-10.

IF: 60.4

- Schmeel FC, Schmeel LC, Kim Y, **Schmidt-Wolf** IGH. Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway. *Hematol Oncol*. 2014 Dec;32(4):197-204.

IF: 2.8

- Gast SM, **Schmidt-Wolf** IGH. Wnt/beta-catenin signaling pathway: a target for novel therapeutic approaches in multiple myeloma. *Drugs Fut* 2013, 38(11): 757.

IF: 0.1

- Jäkel C, Vogt A, Gonzalez-Carmona M, **Schmidt-Wolf** IGH. Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Gastrointestinal Tumors. *Journal of Immunology Research (formerly Clinical & Developmental Immunology)* vol. 2014, Article ID 897214, 12 pages, 2014. doi:10.1155/2014/897214.

IF: 3.3

- Maevis V, Mey U, Schmidt-Wolf G, **Schmidt-Wolf** IGH. Recent advances in the pathophysiology and treatment of hairy cell leukemia. *Blood Cancer J*. 2014 Feb 14;4:e184.

IF: 8.0

- Goldschmidt H, Raab MS, Neben K, Weisel K, **Schmidt-**

Wolf IGH. Strategien beim rezidierten/refraktären multiplen Myelom. Der Onkologe 3/2014. <https://www.springermedizin.de/strategien-beim-rezidierten-refraktaeren-multiplen-myelom/8665172>

IF: 0.1

- Jäkel C, **Schmidt-Wolf** IGH. New adoptive immunotherapy strategy for solid tumors with CIK cells. Expert Opin Biol Ther. 2014 Jul;14(7):905-16.

IF: 3.2

- **Schmidt-Wolf** I. Rezidivtherapie beim Multiplen Myelom. Journal Onkologie, 116-120, 2/2014

IF: 1.5

- **Schmidt-Wolf** IGH, Straka C, Scheid C, Einsele H, Goldschmidt H, Engelhardt M. Behandlung des rezidierten oder refraktären Multiplen Myeloms. DMW 41:2091-2095 (2014)

IF: 0.6

- von Schulz-Hausmann S, Schmeel LC, Schmeel FC, **Schmidt-Wolf** IGH. Targeting the wnt/beta-catenin pathway in RCC. Anticancer Res. 2014 Aug;34(8):4101-8.

IF: 2.0

- Wall I, **Schmidt-Wolf** IGH. Effect of wnt inhibitors in pancreatic cancer. Anticancer Res. 2014 Oct;34(10):5375-80.

IF: 2.0

- Schmeel FC, Schmeel LC, Gast SM, **Schmidt-Wolf** IGH. Adoptive immunotherapy strategies with CIK cells in the treatment of hematological malignancies. Int. J. Mol. Sci. 2014, 15, 14632-14648; doi:10.3390/ijms150814632

IF: 5.9

- Wilmer A, Jansen C, Ko YD, **Schmidt-Wolf** I, Jaehde U. Multiprofessionelles Medikationsmanagement bei Krebspatienten. Forum 29:324-330. 2014

IF: 0.6

- Hoelzer D, Walewski J, Döhner H, Viardot A, Hiddemann W, Baumann A, Serve H, Dührsen U, Hüttmann A, Thiel E, Dengler J, Kneba M, Schaich M, **Schmidt-Wolf** IGH, Beck J, Hertenstein B, Reichle A, Domanska-Czyz K, Fietkau R, Horst HA, Rieder H, Schwartz S, Burmeister T, Gökbuget N. Improved Outcome of Adult Burkitt Non-Hodgkin Lymphoma and Leukemia Patients with Rituximab and a Short-Intensive Chemotherapy; Report of a Large Prospective Multicenter Trial. Blood. 2014 Dec

18;124(26):3870-9

IF: 17.5

- Schmeel LC, Schmeel FC, Kim Y, Blaum-Feder S, Endo T, **Schmidt-Wolf** IGH. In vitro efficacy of cinnarizine against lymphoma and multiple myeloma. *Anticancer Res.* 2015 Feb;35(2):835-41.

IF: 2.0

- [Proetel U](#), [Pletsch N](#), [Lauseker M](#), [Müller MC](#), [Hanfstein B](#), [Krause SW](#), [Kalmanti L](#), [Schreiber A](#), [Heim D](#), [Baerlocher GM](#), [Hofmann WK](#), [Lange E](#), [Einsele H](#), [Wernli M](#), [Kremers S](#), [Schlag R](#), [Müller L](#), [Hänel M](#), [Link H](#), [Hertenstein B](#), [Pfirrmann M](#), [Hochhaus A](#), [Hasford J](#), [Hehlmann R](#), [Saußele S](#); [German Chronic Myeloid Leukemia Study Group](#); [Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung \(SAKK\)](#). [Wernli M](#), [Bargetzi M](#), [Fischer von Weikersthal L](#), [Groß V](#), [Müller S](#), [Hahn M](#), [Schlimok G](#), [Reichert D](#), [Janssen J](#), [Furkert J](#), [Mandel T](#), [Majunke PJ](#), [Paliege R](#), [Reichert P](#), [Fuss H](#), [Neben K](#), [Staiger HJ](#), [Heim D](#), [Gratwohl A](#), [Tichelli A](#), [Korsten S](#), [Henesser D](#), [Le Coutre P](#), [Arnold R](#), [Ludwig WD](#), [Ratei R](#), [Teutsch C](#), [Ludwig F](#), [Urmersbach A](#), [Blau I](#), [Ihle H](#), [Sperling C](#), [Schelenz C](#), [Koschuth A](#), [Kingreen D](#), [Heßling J](#), [Derwahl KM](#), [Oldenkott B](#), [Englisch HJ](#), [Ludwig F](#), [Thiel E](#), [Burmeister T](#), [Notter M](#), [de Wit M](#), [Rothaug W](#), [Büschel G](#), [Beyer J](#), [Dahmen E](#), [Biaggi C](#), [Lämmle B](#), [Friess D](#), [Baerlocher G](#), [Oppliger Leibundgut E](#), [Tobler A](#), [Just M](#), [Schäfer E](#), [Behringer D](#), [Brandt M](#), [Schmiegel W](#), [Vaupel HA](#), [Verbeek W](#), [Ko YD](#), [Weidenhöfer S](#), [Sauerbruch T](#), [Hahn-Ast C](#), [Janzen V](#), **[Schmidt-Wolf I](#)**, [Trenn G](#), [van der Linde M](#), [Pommerien W](#), [Fritz L](#), [Krauter J](#), [Lordick F](#), [Fritsch G](#), [Pflüger KH](#), [Diekmann C](#), [Kullmer J](#), [Doering G](#), [Munzinger H](#), [Hertenstein B](#), [Peyn A](#), [Mayer J](#), [Zácková D](#), [Kujickova J](#), [Stier S](#), [Wejda B](#), [Möller-Faßbender F](#), [Hänel M](#), [Morgner A](#), [Herbst R](#), [Matek W](#), [Lamberti C](#), [Zöller T](#), [Koch B](#), [Marth T](#), [Henzel A](#), [Wagner S](#), [Woska E](#), [Neumann F](#), [Hoffknecht MM](#), [Illmer T](#), [Wolf T](#), [Ehninger G](#), [Kiani A](#), [Platzbecker U](#), [Aul C](#), [Badrakhan CD](#), [Giagounidis A](#), [Flaßhove M](#), [Henneke F](#), [Moritz T](#), [Simon M](#), [Müller LL](#), [Janz R](#), [Eckart M](#), [Häcker B](#), [Rech D](#), [Mackensen A](#), [Krause SW](#), [Staib P](#), [Schlegel F](#), [Wätzig K](#), [Rudolph R](#), [Wattad M](#), [Baur FK](#), [Heit W](#), [Beelen DW](#), [Hüttmann A](#), [Novotny J](#), [Trenschel R](#), [Lindemann A](#), [Linck D](#), [Jäger E](#), [Al-Batran SE](#), [Ottmann OG](#), [Serve H](#), [Reiber T](#), [Semsek D](#), [Waller C](#), [Kühnemund A](#), [Hoeffkes HG](#), [Lambertz H](#), [Schulz L](#), [Tajrobehkar K](#), [Mittermüller J](#), [Rummel MJ](#), [Burchardt A](#), [Pralle H](#), [Runde V](#), [Kleiß M](#), [Westheider J](#), [Hoyer A](#), [Tessen HW](#), [Hesse A](#), [Trümper L](#), [Binder C](#), [Schmidt CA](#), [Hirt C](#), [Sieber M](#), [Eschenburg H](#), [Wilhelm S](#), [Depenbusch R](#), [Rösel S](#), [Eimermacher H](#), [Spohn](#)

[C](#), [Moeller R](#), [Schmitz N](#), [Nickelsen M](#), [Engel E](#), [Haatanen T](#), [Hollburg W](#), [Platz D](#), [Köster H](#), [Bokemeyer C](#), [Schafhausen P](#), [Grote-Metke A](#), [Bechtel B](#), [Hemeier M](#), [Sosada M](#), [Ganser A](#), [Schlegelberger B](#), [Ho AD](#), [Rohlfing S](#), [Dengler J](#), [Petersen V](#), [Porowski P](#), [Hahn L](#), [Dietzfelbinger H](#), [Gröschel W](#), [Bartholomäus A](#), [Pfreundschuh M](#), [Kemmerling M](#), [Hansen R](#), [Reeb M](#), [Link H](#), [Mahlmann S](#), [Mezger J](#), [Schatz M](#), [Schmier M](#), [Gatter J](#), [Neumann S](#), [Heymanns J](#), [Steinmetz HT](#), [Schmitz S](#), [Scheid C](#), [Planker M](#), [Frieling T](#), [Lollert A](#), [Neise M](#), [Schröder M](#), [Greif D](#), [Kempf B](#), [März W](#), [Kremers S](#), [Müller L](#), [Hartmann F](#), [Heil G](#), [Goldmann B](#), [Heinkele P](#), [Gregor M](#), [Theobald M](#), [Fischer T](#), [Thomas S](#), [Hensel M](#), [Plöger C](#), [Schuster D](#), [Brust J](#), [Hieber U](#), [Hehlmann R](#), [Neubauer A](#), [Burchert A](#), [Graeven U](#), [Lange C](#), [Schmidt G](#), [Völkl S](#), [Schmidt B](#), [Hitz H](#), [Spiekermann K](#), [Hiddemann W](#), [Haferlach T](#), [Haferlach C](#), [Schnittger S](#), [Stötzer O](#), [Scheidegger C](#), [Fischer C](#), [Berdel WE](#), [Koppele A](#), [Hebart H](#), [Snaga A](#), [Schmidt P](#), [Hoffmann R](#), [Reschke D](#), [Zirpel I](#), [Sauer M](#), [Lenk G](#), [Eimermacher H](#), [Theilmann L](#), [Sandritter B](#), [Schenk M](#), [Dengler R](#), [Herr W](#), [Krause S](#), [Braun B](#), [Günther E](#), [Wacker A](#), [Pihusch R](#), [Baldus M](#), [Matzdorff A](#), [Pollmeier G](#), [Grimminger W](#), [Hebart H](#), [Geer T](#), [Schanz S](#), [Jürß C](#), [Gassmann W](#), [Seitz K](#), [Kaesberger J](#), [Mück R](#), [Illerhaus G](#), [Denzlinger C](#), [Fiechtner H](#), [Springer G](#), [Hoffmann D](#), [Jacki SH](#), [Kanz L](#), [Bross-Bach U](#), [Döhner H](#), [Stegelman F](#), [Kalhori N](#), [Langer W](#), [Nusch A](#), [Weiß J](#), [Kamp T](#), [Schadeck-Gressel C](#), [Schwerdtfeger R](#), [Josten KM](#), [Klein O](#), [Fett W](#), [Strotkötter H](#), [Maintz C](#), [Groschek M](#), [Schlag R](#), [Elsel W](#), [Schüler F](#), [Dölken G](#), [Lindemann HW](#), [Wolf HH](#), [Schmoll HJ](#), [Braumann D](#), [Hoelzer P](#), [Kleeberg U](#), [Hossfeld D](#), [Lange E](#), [Schubert J](#), [Weischer H](#), [Dürk HA](#), [Kirchner HH](#), [Buß EC](#), [Sievers B](#), [Freier W](#), [Kaiser U](#), [Peest D](#), [Römer E](#), [Hermann T](#), [Fauser A](#), [Valverde ML](#), [Menzel J](#), [Kemper J](#), [Hochhaus A](#), [La Rosée P](#), [Bentz M](#), [Wilhelm S](#), [Prümmer O](#), [Kneba M](#), [Strack U](#), [Schoch R](#), [Severin K](#), [Stauch M](#), [Karbach U](#), [Vehling-Kaiser U](#), [Köchling G](#), [Weiß U](#), [Middeke H](#), [Neuhaus T](#), [Martin H](#), [Fetscher S](#), [Schmielau J](#), [Kämpfe D](#), [Uppenkamp M](#), [Weiß B](#), [Thum P](#), [Wuillemin W](#), [Hofmann WK](#), [Griesshammer M](#), [Tischler HJ](#), [Becker M](#), [Hanfstein B](#), [Müller M](#), [Sauße S](#), [Lunscken C](#), [Kolb HJ](#), [Lutz L](#), [Hentrich M](#), [Nerl C](#), [Wendtner C](#), [Berdel WE](#), [Ladda E](#), [Gnad M](#), [Suna H](#), [Schmidt E](#), [Koschmieder S](#), [Falge C](#), [Wandt H](#), [Wilhelm M](#), [Köhne CH](#), [Schweiger C](#), [Müller-Naendrup C](#), [Frühauf S](#), [Ranft K](#), [Theilmann L](#), [Dencausse Y](#), [Baake G](#), [Ritter PR](#), [Kloke O](#), [Becker M](#), [Göttler B](#), [Völkl S](#), [Schick HD](#), [Weidenhöfer S](#), [Weidinger P](#), [Wacker D](#), [Wehmeyer J](#), [Kreuser ED](#), [Schlenska-Lange A](#), [Edinger R](#), [Andreesen R](#), [Wehmeier A](#), [Stahlhut K](#), [Käfer G](#), [Cerny T](#), [Hess U](#), [Priebe-Richter C](#), [Stange-Budumlu O](#), [Demandt M](#), [Freunek G](#), [Heidemann E](#), [Schleicher J](#), [Mergenthaler HG](#), [Boewer C](#)

[Zeller C](#), [Laubenstein HP](#), [Rendenbach B](#), [Clemens M](#), [Waladkhani AR](#), [Forstbauer H](#), [Müller F](#), [Brettner S](#), [Raghavachar A](#), [Kunzmann V](#), [Goebeler ME](#), [Gmür J](#). Older patients with chronic myeloid leukemia (≥ 65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. [Ann Hematol](#). 2014 Jul;93(7):1167-76.

IF: 2.9

- Schmeel C, Schmeel L, Coch C, **Schmidt-Wolf** IGH. Clinical trials on CIK cells: Update of the international registry on CIK cells (IRCC). *J Cancer Res Clin Oncol* 2015 May;141(5):839-49.

IF: 3.3

- Isaak A, Hauser S, Rogenhofer S, **Schmidt-Wolf** IGH. Matched pair analysis of dendritic cell versus targeted therapy in patients with advanced renal cell carcinoma. *Anticancer Res*. 2015 Mar;35(3):1575-82.

IF: 2.0

- Schmeel LC, Schmeel FC, Kim Y, Blaum-Feder S, Endo T, **Schmidt-Wolf** IGH. Flunarizine exhibits in vitro efficacy against lymphoma and multiple myeloma cells. *Anticancer Res*. 2015;35(3):1369-1376.

IF: 2.0

- **Schmidt-Wolf** I. Kontinuierliche Therapie beim Multiplen Myelom bedeutsam. *Onkologie heute*. S. 33. 09/2014

IF: 0.7

- Sippel C, Kim Y, Wallau A, Brossart P, **Schmidt-Wolf** IGH, Walger P. AML versus ICU: Outcome of septic AML patients in an intensive care setting. *J Cancer Res Clin Oncol*. 2015 Sep;141(9):1645-51.

IF: 3.7

- Bullok KF, Sippel C, **Schmidt-Wolf** IGH. Increased effect of IMiDs by addition of cytokine-induced killer cells in multiple myeloma. *Hematol Oncol*. 2016 Dec;34(4):208-216

IF: 2.8

- Kim Y, **Schmidt-Wolf** IGH. Gentherapie in Deutschland: Von der ersten klinischen Studie bis heute. *Dtsch Med Wochenschr*. 2015 Apr;140(9):684-6.

IF: 0.6

- Mai EK, Bertsch U, Duerig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab

MS, Neben K, Lindemann HW, Zeis M, Gerecke C, **Schmidt-Wolf** IGH, Weisel K, Scheid C, Salwender H, Goldschmidt H. Bortezomib/cyclophosphamide/dexamethasone (VCD) is equal regarding response rates and has a favorable toxicity profile compared to bortezomib/doxorubicin/dexamethasone (PAd) as induction therapy in newly diagnosed, transplant eligible myeloma patients: results from the multicenter, phase III clinical trial GMMG-MM5. *Leukemia*. 2015 Aug;29(8):1721-9.

IF: 8.7

- Kim Y, **Schmidt-Wolf** IGH. Lenalidomide in multiple myeloma. *Expert Rev Anticancer Ther*. 2015 May;15(5):491-7.

IF: 3.6

- Bey I, Bergatt-Kuhl B, Arndt S, Treppner S, **Schmidt-Wolf** I, Hallek M, Wolf J. 8 years patient navigators in the interdisciplinary tumor ambulance of CIO Köln Bonn - a role model for other cancer centers?! *Oncology research and treatment*, Volume: 37., 2014

IF: 2.0

- Sauße S, Krauß MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, **Schmidt-Wolf** I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Müller MC; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. *Blood*. 2015 Jul 2;126(1):42-9.

IF: 17.5

- Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Hillengass J, Raab MS, Schurich B, Munder M, **Schmidt-Wolf** IGH, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: Interim analysis from the prospective GMMG-MM5 trial. *Haematologica*. 2015 Jul;100(7):964-9.

IF: 7.1

- Kim Y, **Schmidt-Wolf** IGH. Multiples Myelom: Die Therapie ist im Fluss. Supplement: Perspektiven der Onkologie. *Dtsch Arztebl* 2015; 112(20): [27]; DOI: 10.3238/PersOnko.2015.05.15.08

IF: 4.8

- Stöhr E, Hänel M, **Schmidt-Wolf** IGH. Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol. 2015 Dec;141(12):2205-12.

IF: 3.7

- Witzens-Harig M, Benner A, Klemmer J, Brants E, Rieger M, McClanahan F, Brandt J, Meissner J, Hensel M, Neben K, Dreger P, Lengfelder E, **Schmidt-Wolf** IGH, Krämer A, Ho AD. Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma. Results of the HD2002 prospective multicenter randomized Phase III trial. Br J Haematol. 2015 Dec;171(5):710-9.

IF: 5.5

- Lauter B, **Schmidt-Wolf** IGH. Prevalence, supplementation and impact of vitamin D deficiency in multiple myeloma patients. Cancer Invest. 2015;33(10):505-9.

IF: 2.4

- Schmeel LC, Schmeel FC, Blaum-Feder S, **Schmidt-Wolf** IGH. In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma. Anticancer Res. 2015 Nov;35(11):5921-6.

IF: 2.0

- Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, **Schmidt-Wolf** I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Sauße S, Hochhaus A, Hehlmann R; SAKK; German CML Study Group. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2016 Mar;30(3):562-9. doi: 10.1038/leu.2015.281. Epub 2015 Oct 14. PMID: 26464170; PMCID: PMC4777774.

IF: 8.7

- Kim Y, **Schmidt-Wolf** IGH. Neue Therapien beim Nieren-Ca. Pharma Fokus Onkologie 12: 38-41; 2015

IF: 2.3

- [van den Berg H](#), [Paulussen M](#), [Le Teuff G](#), [Judson I](#),

[Gelderblom H](#), [Dirksen U](#), [Brennan B](#), [Whelan J](#), [Ladenstein RL](#), [Marec-Berard P](#), [Kruseova J](#), [Hjorth L](#), [Kühne T](#), [Brichard B](#), [Wheatley K](#), [Craft A](#), [Juergens H](#), [Gaspar N](#), [Le Deley MC](#); [Euro-EWING99 Group](#). [Urban Ch](#), [Meister B](#), [Fink FM](#), [Kerbl R](#), [Stollinger O](#), [Schmitt K](#), [Ebetsberger G](#), [Jones N](#), [Ladenstein R](#), [Gadner H](#), [Maes P](#), [Brichard B](#), [Mazzeo F](#), [Gil T](#), [Dhooge C](#), [Vermorken JB](#), [Klein A](#), [Kruseova J](#), [Krarup-Hansen A](#), [Nielsen O](#), [Capra M](#), [Pautard B](#), [Rialland X](#), [Maillart P](#), [Plouvier E](#), [Vérité C](#), [Bui N'guyen B](#), [Boutard P](#), [Delcambre C](#), [Bay JO](#), [Demeocq F](#), [Couillault G](#), [Isambert N](#), [Plantaz D](#), [Desfachelles AS](#), [Piguet C](#), [Marec-Bérard P](#), [Blay JY](#), [Gentet JC](#), [Duffaud F](#), [Bertucci F](#), [Sirvent N](#), [Schmitt C](#), [Rios M](#), [Corradini N](#), [Rolland F](#), [Deville A](#), [Thyss A](#), [Michon J](#), [Tabone MD](#), [Pierga JY](#), [Millot F](#), [Munzer M](#), [Edan C](#), [Vannier JP](#), [Guillemet C](#), [Brun E](#), [Berger C](#), [Castex MP](#), [Roche H](#), [Lejars O](#), [Linassier C](#), [Oberlin O](#), [Le Cesne A](#), [Bauer S](#), [Ebeling P](#), [Flasshove M](#), [Hartmann JT](#), [Reichardt P](#), [Mertens R](#), [Osieka R](#), [Gnekow A](#), [Schlimok G](#), [Henze G](#), [Thuss-Patience P](#), [Wickmann L](#), [Reichardt P](#), [Potenberg J](#), [Reichardt P](#), [Bode U](#), [Schmidt-Wolf IG](#), [Eberl W](#), [Wolff T](#), [Pekrun A](#), [Hofmann A](#), [Andler W](#), [Schneider D](#), [Lauterbach I](#), [Zickler P](#), [Göbel U](#), [Borkhardt A](#), [Sauerbrey A](#), [Holter W](#), [Bauer S](#), [Ebeling P](#), [Flasshove M](#), [Eggert A](#), [Klingebiel T](#), [Niemeyer C](#), [Heinz J](#), [Reiter A](#), [Rummel M](#), [Runde V](#), [Lakomek M](#), [Trümper L](#), [Beck J](#), [Dölken G](#), [Lindemann HW](#), [Körholz D](#), [Schmoll HJ](#), [Schneppenheim R](#), [Hossfeld DK](#), [Bokemeyer C](#), [Keles H](#), [Welte K](#), [Klein C](#), [Kulozik A](#), [Egerer G](#), [Cyran J](#), [Strumberg D](#), [Freier W](#), [Graf N](#), [Pfreundschuh M](#), [Gruhn B](#), [Leipold A](#), [Bentz M](#), [Wehinger H](#), [Schrappe M](#), [Nolte H](#), [Berthold F](#), [Wolf J](#), [Sternschulte W](#), [Voelpel S](#), [Frieling T](#), [Moessner J](#), [Selle D](#), [Bucsky D](#), [Bartels H](#), [Mohren M](#), [Fischer T](#), [Kluba U](#), [Gutjahr P](#), [Dittrich M](#), [Reiter S](#), [Dürken M](#), [Neubauer A](#), [Beyer J](#), [Christiansen H](#), [Erdlenbruch B](#), [Burdach S](#), [Schmid I](#), [Meyer zum Büschenfelde C](#), [Peschel C](#), [Oduncu F](#), [Jürgens H](#), [Berdel W](#), [Held H](#), [Hofmann-Wackersreuther G](#), [Müller H](#), [Peters O](#), [Andreesen R](#), [Krause S](#), [Heits F](#), [Geib-König R](#), [Kasbohm M](#), [Bürger D](#), [Burghard R](#), [Dickerhoff R](#), [Bielack S](#), [Feddersen I](#), [Clemens MR](#), [Handgretinger R](#), [Hartmann JT](#), [Debatin KM](#), [Mayer-Steinacker R](#), [Schoengen A](#), [Schlegel P](#), [Lee V](#), [Chik KW](#), [van den Berg H](#), [Rodenhuis S](#), [Gelderblom AJ](#), [Hoogerbrugge P](#), [Bökkerink JP](#), [Pieters R](#), [Corbett R](#), [Österlundh G](#), [Behrendtz M](#), [Holmqvist BM](#), [Hjorth L](#), [Petersen C](#), [Jakobson Å](#), [Hjalmars U](#), [Ljungman G](#), [Angst R](#), [Kühne T](#), [Paulussen M](#), [Leyvraz S](#), [Rischewski J](#), [Feldges A](#), [Greiner J](#), [Hess U](#), [Exner GU](#), [Niggli F](#), [Knuth A](#), [King D](#), [McCarthy A](#), [Henry P](#), [Morland B](#), [Rees H](#), [Nicholson J](#), [Traunecker H](#), [Wallace H](#), [Ronghe M](#), [Simpson E](#), [Cowie F](#), [White J](#), [Picton S](#), [Lewis I](#), [Leahy M](#), [Stark D](#), [Selby PJ](#), [Heney D](#), [Pizer B](#), [McDowell H](#), [Michalski A](#), [Whelan J](#),

[Chisholm J](#), [Pritchard-Jones K](#), [Judson I](#), [Brennan B](#), [Hale J](#), [Verrill M](#), [Walker D](#), [Sokal M](#), [Wheeler K](#), [Lee V](#), [Gerrard M](#), [Woll P](#), [Lorigan P](#), [Robinson M](#), [Kohler J](#). Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. [Eur J Cancer](#). 2015 Nov;51(16):2453-64. doi: 10.1016/j.ejca.2015.06.123. Epub 2015 Aug 10.

IF: 7.3

- [Haaß W](#), [Kleiner H](#), [Weiß C](#), [Haferlach C](#), [Schlegelberger B](#), [Müller MC](#), [Hehlmann R](#), [Hofmann WK](#), [Fabarius A](#), [Seifarth W](#); [Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung](#); [German CML Study Group](#). [Wernli M](#), [Bargetzi M](#), [Fischer von Weikersthal L](#), [Gro V](#), [Müller S](#), [Hahn M](#), [Schlimok G](#), [Reichert D](#), [Janssen J](#), [Furkert J](#), [Mandel T](#), [Majunke PJ](#), [Paliege R](#), [Reichert P](#), [Fuss H](#), [Neben K](#), [Staiger HJ](#), [Heim D](#), [Gratwohl A](#), [Tichelli A](#), [Korsten S](#), [Henesser D](#), [Le Coutre P](#), [Arnold R](#), [Ludwig WD](#), [Ratei R](#), [Teutsch C](#), [Ludwig F](#), [Urmersbach A](#), [Blau I](#), [Ihle H](#), [Sperling C](#), [Schelenz C](#), [Koschuth A](#), [Kingreen D](#), [Heßling J](#), [Derwahl KM](#), [Oldenkott B](#), [Englisch HJ](#), [Ludwig F](#), [Thiel E](#), [Burmeister T](#), [Notter M](#), [de Wit M](#), [Rothaug W](#), [Büschel G](#), [Beyer J](#), [Dahmen E](#), [Biaggi C](#), [Lämmle B](#), [Friess D](#), [Baerlocher G](#), [Oppliger Leibundgut E](#), [Tobler A](#), [Just M](#), [Schäfer E](#), [Behringer D](#), [Brandt M](#), [Schmiegel W](#), [Vaupel HA](#), [Verbeek W](#), [Ko YD](#), [Weidenhöfer S](#), [Sauerbruch T](#), [Hahn-Ast C](#), [Janzen V](#), **[Schmidt-Wolf I](#)**, [Trenn G](#), [van der Linde M](#), [Pommerien W](#), [Fritz L](#), [Krauter J](#), [Lordick F](#), [Fritsch G](#), [Pflüger KH](#), [Diekmann C](#), [Kullmer J](#), [Doering G](#), [Munzinger H](#), [Hertenstein B](#), [Peyn A](#), [Mayer J](#), [Zácková D](#), [Kujickova J](#), [Stier S](#), [Wejda B](#), [Möller-Faßbender F](#), [Hänel M](#), [Morgner A](#), [Herbst R](#), [Matek W](#), [Lamberti C](#), [Zöller T](#), [Koch B](#), [Marth T](#), [Henzel A](#), [Wagner S](#), [Woska E](#), [Neumann F](#), [Hoffknecht MM](#), [Illmer T](#), [Wolf T](#), [Ehninger G](#), [Kiani A](#), [Platzbecker U](#), [Aul C](#), [Badrakhan CD](#), [Giagounidis A](#), [Flaßhove M](#), [Henneke F](#), [Moritz T](#), [Simon M](#), [Müller LL](#), [Janz R](#), [Eckart M](#), [Häcker B](#), [Rech D](#), [Mackensen A](#), [Krause SW](#), [Staib P](#), [Schlegel F](#), [Wätzig K](#), [Rudolph R](#), [Wattad M](#), [Baur FK](#), [Heit W](#), [Beelen DW](#), [Hüttmann A](#), [Novotny J](#), [Trenschel R](#), [Lindemann A](#), [Linck D](#), [Jäger E](#), [Al-Batran SE](#), [Ottmann OG](#), [Serve H](#), [Reiber T](#), [Semsek D](#), [Waller C](#), [Kühnemund A](#), [Hoeffkes HG](#), [Lambertz H](#), [Schulz L](#), [Tajrobehkar K](#), [Mittermüller J](#), [Rummel MJ](#), [Burchardt A](#), [Pralle H](#), [Runde V](#), [Klei M](#), [Westheider J](#), [Hoyer A](#), [Tessen HW](#), [Hesse A](#), [Trümper L](#), [Binder C](#), [Schmidt CA](#), [Hirt C](#), [Sieber M](#), [Eschenburg H](#), [Wilhelm S](#), [Depenbusch R](#), [Rösel S](#), [Eimermacher H](#), [Spohn C](#), [Moeller R](#), [Schmitz N](#), [Nickelsen M](#), [Engel E](#), [Haatanen T](#), [Hollburg W](#), [Platz D](#), [Köster H](#), [Bokemeyer C](#), [Schafhausen P](#), [Grote-Metke A](#), [Bechtel B](#), [Hemeier M](#), [Sosada M](#), [Ganser](#)

[A](#), [Schlegelberger B](#), [Ho AD](#), [Rohlfing S](#), [Dengler J](#), [Petersen V](#), [Porowski P](#), [Hahn L](#), [Dietzfelbinger H](#), [Gröschel W](#), [Bartholomäus A](#), [Pfreundschuh M](#), [Kemmerling M](#), [Hansen R](#), [Reeb M](#), [Link H](#), [Mahlmann S](#), [Mezger J](#), [Schatz M](#), [Schmier M](#), [Gatter J](#), [Neumann S](#), [Heymanns J](#), [Steinmetz HT](#), [Schmitz S](#), [Scheid C](#), [Planker M](#), [Frieling T](#), [Lollert A](#), [Neise M](#), [Schröder M](#), [Greif D](#), [Kempf B](#), [März W](#), [Kremers S](#), [Müller L](#), [Hartmann F](#), [Heil G](#), [Goldmann B](#), [Heinkele P](#), [Gregor M](#), [Theobald M](#), [Fischer T](#), [Thomas S](#), [Hensel M](#), [Plöger C](#), [Schuster D](#), [Brust J](#), [Hieber U](#), [Hehlmann R](#), [Neubauer A](#), [Burchert A](#), [Graeven U](#), [Lange C](#), [Schmidt G](#), [Völkl S](#), [Schmidt B](#), [Hitz H](#), [Spiekermann K](#), [Hiddemann W](#), [Haferlach T](#), [Haferlach C](#), [Schnittger S](#), [Stötzer O](#), [Scheidegger C](#), [Fischer C](#), [Berdel WE](#), [Koppele A](#), [Hebart H](#), [Snaga A](#), [Schmidt P](#), [Hoffmann R](#), [Reschke D](#), [Zirpel I](#), [Sauer M](#), [Lenk G](#), [Eimermacher H](#), [Theilmann L](#), [Sandritter B](#), [Schenk M](#), [Dengler R](#), [Herr W](#), [Krause S](#), [Braun B](#), [Günther E](#), [Wacker A](#), [Pihusch R](#), [Baldus M](#), [Matzdorff A](#), [Pollmeier G](#), [Grimminger W](#), [Hebart H](#), [Geer T](#), [Schanz S](#), [Jür C](#), [Gassmann W](#), [Seitz K](#), [Kaesberger J](#), [Mück R](#), [Illerhaus G](#), [Denzlinger C](#), [Fiechtner H](#), [Springer G](#), [Hoffmann D](#), [Jacki SH](#), [Kanz L](#), [Bross-Bach U](#), [Döhner H](#), [Stegelman F](#), [Kalhori N](#), [Langer W](#), [Nusch A](#), [Wei J](#), [Kamp T](#), [Schadeck-Gressel C](#), [Schwerdtfeger R](#), [Josten KM](#), [Klein O](#), [Fett W](#), [Strotkötter H](#), [Maintz C](#), [Groschek M](#), [Schlag R](#), [Elsel W](#), [Schüler F](#), [Dölken G](#), [Lindemann HW](#), [Wolf HH](#), [Schmoll HJ](#), [Braumann D](#), [Hoelzer P](#), [Kleeberg U](#), [Hossfeld D](#), [Lange E](#), [Schubert J](#), [Weischer H](#), [Dürk HA](#), [Kirchner HH](#), [Bu EC](#), [Sievers B](#), [Freier W](#), [Kaiser U](#), [Peest D](#), [Römer E](#), [Hermann T](#), [Fauser A](#), [Valverde ML](#), [Menzel J](#), [Kemper J](#), [Hochhaus A](#), [La Rosée P](#), [Bentz M](#), [Wilhelm S](#), [Prümmer O](#), [Kneba M](#), [Strack U](#), [Schoch R](#), [Severin K](#), [Stauch M](#), [Karch U](#), [Vehling-Kaiser U](#), [Köchling G](#), [Wei U](#), [Middeke H](#), [Neuhaus T](#), [Martin H](#), [Fetscher S](#), [Schmielau J](#), [Kämpfe D](#), [Uppenkamp M](#), [Wei B](#), [Thum P](#), [Wuillemin W](#), [Hofmann WK](#), [Griesshammer M](#), [Tischler HJ](#), [Becker M](#), [Hanfstein B](#), [Müller M](#), [Sauße S](#), [Lunscken C](#), [Kolb HJ](#), [Lutz L](#), [Hentrich M](#), [Nerl C](#), [Wendtner C](#), [Berdel WE](#), [Ladda E](#), [Gnad M](#), [Suna H](#), [Schmidt E](#), [Koschmieder S](#), [Falge C](#), [Wandt H](#), [Wilhelm M](#), [Köhne CH](#), [Schweiger C](#), [Müller-Naendrup C](#), [Frühauf S](#), [Ranft K](#), [Theilmann L](#), [Dencausse Y](#), [Baake G](#), [Ritter PR](#), [Kloke O](#), [Becker M](#), [Göttler B](#), [Völkl S](#), [Schick HD](#), [Weidenhöfer S](#), [Weidinger P](#), [Wacker D](#), [Wehmeyer J](#), [Kreuser ED](#), [Schlenska-Lange A](#), [Edinger R](#), [Andreesen R](#), [Wehmeier A](#), [Stahlhut K](#), [Käfer G](#), [Cerny T](#), [Hess U](#), [Priebe-Richter C](#), [Stange-Budumlu O](#), [Demandt M](#), [Freunek G](#), [Heidemann E](#), [Schleicher J](#), [Mergenthaler HG](#), [Boewer C](#), [Zeller C](#), [Laubenstein HP](#), [Rendenbach B](#), [Clemens M](#), [Waladkhani AR](#), [Forstbauer H](#), [Müller F](#), [Brettner S](#), [Raghavachar A](#), [Kunzmann V](#), [Goebeler ME](#), [Gmür J](#). Clonal

Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy. [PLoS One](#). 2015 Jun 18;10(6):e0129648. doi: 10.1371/journal.pone.0129648. eCollection 2015.

IF: 2.7

- Rombo R, Weiher H, **Schmidt-Wolf** IGH. Effect of chaetocin on renal cell carcinoma cells and cytokine-induced killer cells. *Ger Med Sci*. 2016 Apr 18;14:Doc04. doi: 10.3205/000231.

IF: 1.2

- Bärtsch MA, Schlenzka J, Mai E, Merz M, Hillengaß J, Raab MS, Hose D, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, **Schmidt-Wolf** IGH, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLapsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. *BMC Cancer* 16:290. DOI 10.1186/s12885-016-2321-2; 2016

IF: 3.2

- Schmeel LC, Schmeel FC, Schmidt-Wolf IGH. Clofibrate demonstrates efficacy in vitro treatment of lymphoma and multiple myeloma. *Anticancer Res*. 2016 Jul;36(7):3395-400.

IF: 2.0

- Nwangwu CA, Weiher H, **Schmidt-Wolf** IGH. Increase of CIK cell efficacy by up-regulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma. *Hematological Oncol*. 2017 Dec;35(4):719-725. doi: 10.1002/hon.2326. Epub 2016 Jul 19.

IF: 2.8

- Esser L, Weiher H, **Schmidt-Wolf** IGH. Increased efficacy of brentuximab vedotin (SGN-35) in combination with CIK cells in lymphoma. *Int J Mol Sci*. 2016 Jul 1;17(7).

IF 5.9

- Schirmbeck N, Mey U, Olivieri A, Hensel M, Flieger D, **Schmidt-Wolf** IGH. Salvage chemotherapy with R-DHAP in patients with relapsed or refractory non-Hodgkin lymphoma. *Cancer Invest*. 2016 Sep 13;34(8):361-72.

IF: 2.4

- **Schmidt-Wolf** IGH, Plass C, Byrd JC, Frevel K, Pietsch T, Waha A. Assessment of promotor methylation identifies PTCH as a putative tumor-suppressor gene in human CLL. *Anticancer Res* 2016 Sep;36(9):4515-9.

IF: 2.0

- Jansen C, **Schmidt-Wolf** I, Jaehde U. Patientenindividuelles Nebenwirkungsmanagement bei intravenöser Tumorthherapie. *Onkologische Pharmazie*, S. 16-20, Nr. 1/2016

IF: 0.1

- Messina CS, Weiher H, **Schmidt-Wolf** IGH. Targeting Prostate Cancer with a Combination of WNT Inhibitors and a Bi-functional Peptide. [Anticancer Res.](#) 2017 Feb;37(2):555-559.

IF: 2.0

- Hütter-Krönke ML, Benner A, Döhner K, Krauter J, Weber D, Moessner M, Köhne CH, Horst HA, **Schmidt-Wolf** I, Rummel M, Götze K, Koller E, Petzer A, Salwender H, Fiedler W, Kirchen H, Haase D, Kremers S, Theobald M, Matzdorff AC, Ganser A, Döhner H, Schlenk RF. Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-*trans* retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. *Haematologica*. 2016 Jul;101(7):839-45.

IF: 7.1

- Yordanova A, Ahmadzadehfar H, Gonzalez-Carmona M, Strassburg C, Mayer K, Feldmann G, **Schmidt-Wolf** I, Lingohr P, Fischer S, Kristiansen G, Essler M..A step-by-step clinical approach for the management of neuroendocrine tumours. *Horm Metab Res* 49: 77-85 (2017)

IF: 2.6

- Hendrayana T, Wilmer A, Kurth V, Wipping D, **Schmidt-Wolf** IGH, Jaehde U. Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: from Scientific Literature Evidence-Based to Daily Clinical Routine Application. *Sci. Pharm.* 2017, 85(1), 8; doi:10.3390/scipharm85010008 - 27 February 2017.

IF:2.9

- Kim Y, **Schmidt-Wolf** IGH. Elotuzumab. *Internistische Praxis* 58, Heft 4, 709-714; 2018.

IF: 0.0

- Kim Y, **Schmidt-Wolf** IGH. Elotuzumab. Gynäkologische Praxis 43, 160-165; 2018.

IF: 0.0

- Gaidzik VI, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, Krönke J, Kapp-Schworer S, Krämer D, Horst HA, **Schmidt-Wolf** IGH, Held G, Kündgen A, Ringhoffer M, Götze K, Kindler T, Fiedler W, Wattad M, Schlenk RF, Bullinger L, Teleanu V, Schlegelberger B, Thol F, Heuser M, Ganser A, Döhner H, Döhner K, for the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). Persistence of *DNMT3A* mutant transcript levels by minimal residual disease monitoring in intensively treated patients with acute myeloid leukemia: Results of the AML Study Group (AMLSG). Leukemia. 2018 Jan;32(1):30-37. doi: 10.1038/leu.2017.200. Epub 2017 Jun 23.

IF: 8.7

- Krebs S, Starbatty B, Skoetz N, **Schmidt-Wolf** I, Brandts C, Bischoff M, Wolf J, Glossmann JP. „Nutzung lokaler onkologischer Standard Operating Procedures und onkologischer Leitlinien: Eine Umfrage unter 1.600 Ärzten an 4 Onkologischen Spitzenzentren der Deutschen Krebshilfe“. Onkologie heute 5/2017.

IF: 0.1

- Baertsch MA, Schlenzka J, Lisenko K, Krzykalla J, Becker N, Weisel K, Noppeney R, Martin H, Lindemann HW, Haenel M, Nogai A, Scheid C, Salwender H, Fenk R, Graeven U, Reimer P, Schmidt-Hieber M, Goerner M, **Schmidt-Wolf** IGH, Klein S, Ho AD, Goldschmidt H, Wuchter P. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE. Eur J Haematol. 2017 Jul;99(1):42-50. doi: 10.1111/ejh.12888. Epub 2017 May 24. PMID: 28370401.

IF: 2.2

- Schmeel C, Schmeel C, Young Kim, Blaum-Feder S, **Schmidt-Wolf** IGH. The path of the Wnt: Griseofulvin in Multiple Myeloma. ANTICANCER RESEARCH 37: 2289-2295 (2017)

IF: 2.0

- Stephan D, Weiher H, Schmidt-Wolf IGH. CIK Cells and HDAC Inhibitors in Multiple Myeloma. Int J Mol Sci. 2017 Apr 29;18(5):945

IF: 4.2

- Merz M, Jauch A, Hielscher T, Mai EK, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf I, Scheid C, Haenel M, Weisel K, Goldschmidt H, Hillengass J. Longitudinal fluorescence *in situ* hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. *Haematologica*. 2017 Aug;102(8):1432-1438. doi: 10.3324/haematol.2017.168005. Epub 2017 May 11. PMID: 28495913; PMCID: PMC5541876.

IF: 7.1

- Kasenda B, Ihorst G, Schroers R, Korfel A, **Schmidt-Wolf** IGH, Egerer G, von Baumgarten L, Röth A, Stilgenbauer S, Möhle R, Binder M, Keller U, Kneba M, Wolf HH, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma – a prospective multicentre trial by the German Cooperative PCNSL study group. *Leukemia* 2017 Dec;31(12):2623-2629. doi: 10.1038/leu.2017.170.

IF: 8.7

- Schmeel LC, Schmeel FC, Kim Y, Blaum-Feder S, **Schmidt-Wolf** IGH. *In-vitro* apoptosis induction by fenofibrate in lymphoma and multiple myeloma. *Anticancer Res*, 37: 3513-3520 (2017)

IF: 2.0

- Merz M, Jauch A, Hielscher T, Bochtler T, Hegenbart U, Schönland S, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, **Schmidt-Wolf** IGH, Scheid C, Haenel M, Weisel K, Goldschmidt H. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma treated within the GMMG HD4 trial. *Blood Adv*. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.

IF: 4.6

- Emekwue NPC, Weiher H, **Schmidt-Wolf** IGH. Ethacrynic acid and ciclopiroxolamine in various cancer cells. *International Journal of Hematology and Therapy*, DOI: 10.15436/2381-1404.18.1666. 2018

IF: 0.5

- Biederbick KD, Schmidt-Wolf IGH. Efficacy of cytokine-induced killer cells targeting CD40 and GITR. *Oncol Lett*.

2019 Feb;17(2):2425-2430.

IF: 2.3

- Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Böhme C, Burchert W, Dietlein M, Drzezga A, Fabry U, Feldmann G, Heidenreich A, Heinzel A, Herrmann K, Heyll A, Höhling C, Kreuzer C, Laufer D, Mengel R, Mottaghy FM, Müller HW, Müller SC, Ost E, Rahbar K, Reifenhäuser W, Schäfers M, Schlenkhoff C, Schmidt M, **Schmidt-Wolf** I, Wildenhain C, Zimmer B, Essler M. [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein]. Urologe A. 2018 Jun;57(6):709-713. doi: 10.1007/s00120-018-0642-2. Review.

IF: 0.5

- Al-Dali A, Weiher H, **Schmidt-Wolf** IGH. Utilizing ethacrynic acid and ciclopirox olamine in liver cancer. Oncology Letters (spandidos publications) 2018 Nov;16(5):6854-6860. doi: 10.3892/ol.2018.9472.

IF: 2.3

- Jansen C, **Schmidt-Wolf** IGH, Ko YD, Jaehde U. Multiprofessionelles Medikationsmanagement – mehr Arzneimitteltherapiesicherheit für Tumorkrankte. best practice onkologie. 3-4, 168-172, 2017

IF: 0.1

- Hollunder S, Herrlinger U, Zipfel M, Schmolders J, Janzen V, Thiesler T, Güresir E, Schröck A, Far F, Pietsch T, Pantelis D, Thomas D, Vornholt S, Ernstmann N, Manser T, Neumann M, Funke B, Schmidt-Wolf IGH. Cross-sectional increase of adherence to multidisciplinary tumor board decisions. BMC Cancer. 2018 Sep 29;18(1):936.

IF 3.2

- Kim Y, **Schmidt-Wolf** IGH. Elotuzumab (Empliciti®) – ein moderner monoklonaler Antikörper. Onkologie heute. 51-54. 04/2019.

IF: 0.1

- Hillebrand RM, Vogt A, Strassburg CP, Gonzalez-Carmona MA, **Schmidt-Wolf** IGH. Immune checkpoint CD40/CD40 ligand activates dendritic and effector cells against human renal carcinoma cells. Anticancer Res, 2019 Sep;39(9):4643-4652. doi: 10.21873/anticancerres.13645.

IF: 2.0

- Garofano F, Gonzalez-Carmona MA, Skowasch D, Schmidt-Wolf R, Abramian A, Hauser S, Strassburg CP, Schmidt-

Wolf IGH. Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. *Int J Mol Sci.* 2019 Sep 3;20(17):4307.

IF 5.9

- Setiawan MF, Rudan O, Vogt A, Gonzalez-Carmona MA, Langhans B, Schmidt-Wolf R, Garofano F, Strassburg CP, Lasarte JJ, Casares N, Lozano T, Weiher H, **Schmidt-Wolf** IGH. FOXP3 Inhibitory Peptide P60 Increases Efficacy of Cytokine-induced Killer Cells Against Renal and Pancreatic Cancer Cells. *Anticancer Res.* 2019 Oct;39(10):5369-5374.

IF: 2.0

- Budde M, Kuhn W, Keyver-Paik MD, Bootz F, Kalff JC, Müller SC, Bieber T, Brossart P, Vatter H, Herrlinger U, Wirtz DC, Schild HH, Kristiansen G, Pietsch T, Aretz S, Geiser F, Radbruch L, Reich RH, Strassburg CP, Skowasch D, Essler M, Ernstmann N, Landsberg J, Funke B, **Schmidt-Wolf** IGH. A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center. *BMC Cancer.* 2019 Oct 30;19(1):1024. doi: 10.1186/s12885-019-6241-9.

IF: 3.2

- Mayer K, Hahn-Ast C, Schwab K, Glasmacher A, **Schmidt-Wolf** IGH, Brossart P, von Lilienfeld-Toal M. Long-term follow-up of Salvage Treatment for Relapsed AML with Cladribine, high dose Cytarabine and Idarubicin (CAI). *Eur J Haematol.* 2020 Jun;104(6):538-545. doi: 10.1111/ejh.13395. Epub 2020 Mar 10.

IF: 2.2

- Freytag M, Herrlinger U, Hauser S, Bauernfeind FG, Gonzales-Carmona M, Landsberg J, Buermann J, Vatter H, Holderried T, Send T, Schumacher M, Koscielny A, Feldmann G, Heine M, Skowasch D, Schäfer N, Funke B, Neumann M, **Schmidt-Wolf** IGH. Higher number of multidisciplinary tumor board meetings per case leads to further improved clinical outcome. *BMC Cancer.* 2020 Apr 28;20(1):355. doi: 10.1186/s12885-020-06809-1.

IF: 3.2

- Dehno MN, Li Y, Weiher H, **Schmidt-Wolf** IGH. Increase in efficacy of checkpoint inhibition by cytokine-induced-killer cells as a combination immunotherapy for renal cancer. *Int J Mol Sci.* 2020 Apr 27;21(9). pii: E3078. doi: 10.3390/ijms21093078.

IF: 5.9

- Zhang Y, Garofano F, Schmid M, Krawitz P, Essler M,

Schmidt-Wolf IGH. Integrative analysis of key candidate genes and signaling pathway in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics. *Investigational New Drugs*. 2020 Dec;38(6):1717-1729.

IF: 3.5

- Zhang Y, **Schmidt-Wolf** IGH. Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. *J Cell Physiol*. 2020 Jun 2. doi: 10.1002/jcp.29827. Epub ahead of print. PMID: 32484595.

IF: 5.5

- Garofano F, Schmidt-Wolf IGH. High Expression of Cannabinoid Receptor 2 on Cytokine-Induced Killer Cells and Multiple Myeloma Cells. *Int J Mol Sci*. 2020 May 27;21(11):3800.

IF: 5.9

- Wu X, Zhang Y, Li Y, **Schmidt-Wolf** IGH. Increase of Antitumoral Effects of Cytokine-Induced Killer Cells by Antibody-Mediated Inhibition of MICA Shedding. *Cancers (Basel)*. 2020 Jul 7;12(7):1818. doi: 10.3390/cancers12071818. PMID: 32645836; PMCID: PMC7408690.

IF: 6.1

- de Olalla EVDG, Garofano F, Weiher H, Muders MH, Förster S, **Schmidt-Wolf** IGH. Presence of the transmembrane protein Neuropilin in Cytokine-induced killer cells. *Anticancer Res*. 2020 Oct;40(10):5489-5496. doi: 10.21873/anticancer.14560.

IF: 2.0

- Seidel S, Pels H, Schlömer S, Kowoll A, Fliessbach K, Engert A, Vogt-Schaden M, Egerer G, Reichmann H, Schackert G, Kroschinsky F, Deckert M, Herrlinger U, Klockgether T, Fimmers R, Bode U, **Schmidt-Wolf** IGH, Schlegel U. Cure for primary CNS lymphoma? Twenty years follow-up of patients treated within a pilot/phase II-trial on the Bonn protocol. *Neurology*. 2020 Sep 28;10.1212/WNL.0000000000010949. doi: 10.1212/WNL.0000000000010949.

IF: 8.8

- Zhang Y, Ellinger H, Weiher H, Skowasch D, Schmid M, Ritter M, **Schmidt-Wolf** IGH. Mini-review on CIK cells in metastatic renal cancer. *Cancers (Basel)*. 2020 Sep 1;12(9):2471. doi: 10.3390/cancers12092471.

IF: 6.1

- Schmies CC, Rolshoven G, Idris RM, Renn C, Schäkel L, Al-Hroub H, Wang Y, **Schmidt-Wolf** IGH, Zimmermann H, Yegutkin GG, Müller CE. Fluorescent probes for ecto-5'-nucleotidase (CD73). *ACS Med Chem*

Lett. 2020 Sep 3;11(11):2253-2260. doi: 10.1021/acsmmedchemlett.0c00391. eCollection 2020 Nov 12.

IF: 3.7

- Vucur C, Wirtz D, Weinhold L, Schmid M, **Schmidt-Wolf** IGH, Jaehde U. Drug-Related Problems in Head and Neck Cancer Patients. International Journal of Clinical Pharmacy (IJCP). J Oncol Pharm Pract. 2020 Oct 6;1078155220962178. doi: 10.1177/1078155220962178.

IF: 1.6

- Slomka A, Mocan T, Wang B, Nenu I, Urban SK, Gonzalez-Carmona M, **Schmidt-Wolf** IGH, Lukacs-Kornek V, Strassburg CP, Spârchez Z, Kornek M. EVs as Potential new Therapeutic Tool/Target in Gastrointestinal Cancer and HCC. Cancers (Basel). 2020 Oct 17;12(10):3019. doi: 10.3390/cancers12103019.

IF: 6.1

- Wu X, Zhang Y, Li Y, **Schmidt-Wolf** IGH. Improvements in flow cytometry-based cytotoxicity assay. Cytometry A. 2020 Oct 17. doi: 10.1002/cyto.a.24242

IF: 3.4

- Sadeghlar F, Vogt A, Mohr RU, van Beekum K, Kornek M, Weismüller TJ, Branchi V, Matthäei H, Toma M, **Schmidt-Wolf** IGH, Kalff J, Strassburg C, Gonzalez-Carmona M. Induction of Cytotoxic Effector Cells towards Cholangiocellular, Pancreatic, and Colorectal Tumor Cells by Activation of the Immune Checkpoint CD40/CD40L on Dendritic Cells. Cancer Immunology Immunotherapy 2020. <http://link.springer.com/article/10.1007/s00262-020-02746-x>

IF: 5.0

- Jäger A, Setiawan M, Beins E, **Schmidt-Wolf** IGH, Konermann A. Analogous modulation of inflammatory responses by the endocannabinoid system in periodontal ligament cells and microglia. Head&Face Medicine. 16, Article number: 26 (2020). <https://doi.org/10.1186/s13005-020-00244-0>

IF: 1.9

- Sharma A, Liu H, Herwig-Carl MC, Dakal TC, **Schmidt-Wolf** IGH. Epigenetic regulatory enzymes: mutation prevalence and coexistence in cancers. Cancer Investigation 2021.

IF: 2.4

- Li Y, Sharma A, Bloemendal MWJR, Schmidt-Wolf R, Kornek M, **Schmidt-Wolf** IGH. PD-1 blockade enhances cytokine-induced killer cell-mediated cytotoxicity in B-cell non-Hodgkin lymphoma cell lines. Oncol Lett. 2021 Aug;22(2):613. doi: 10.3892/ol.2021.12874. Epub 2021 Jun 23. PMID: 34257721; PMCID: PMC8243082. IF: 1.9
- Rüdiger R, Geiser F, Ritter M, Brossart P, Keyver-Paik MD, Faridi A, Vatter H, Bootz F, Landsberg J, Kalff JC, Herrlinger U, Kristiansen G, Pietsch T, Aretz S, Thomas D, Radbruch L, Kramer FJ, Strassburg CP, Gonzalez-Carmona M, Skowasch D, Essler M, Schmid M, Nadal J, Ernstmann N, Sharma A, Funke B, **Schmidt-Wolf** IGH. No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany. BMC Cancer. 2021 May 10;21(1):526. doi: 10.1186/s12885-021-08141-8. PMID: 33971845; PMCID: PMC8108356.

IF: 3.2

- Hausen A, Henschel D, Heuser R, Harnischmacher M, Klöß C, Pröbstl A, **Schmidt-Wolf** IGH, Strassburg C, Kalff JC, von Websky MW. Entwicklung und Implementierung einer ernährungsmedizinischen Strategie zur optimierten Versorgung von Patienten mit Mangelernährung in einem Großklinikum. June 2021. [Zentralblatt für Chirurgie](https://doi.org/10.1055/a-1481-9227) 146(03):283-295. DOI: [10.1055/a-1481-9227](https://doi.org/10.1055/a-1481-9227)

IF: 0.8

- Margold M, Seidel S, Kowalski T, Ladigan-Badura S, Baraniskin A, Schroers R, Frey AV, **Schmidt-Wolf** IGH, Herrlinger U, Korfel A, Schlegel U. The value of bone marrow biopsy for staging of patients with primary CNS lymphoma. Neuro Oncol. 2021 Dec 1;23(12):2076-2084. doi: 10.1093/neuonc/noab109. PMID: 33984138; PMCID: PMC8643483.

IF: 10.2

- Vogt A, Sadeghlar F, Ayub TH, Schneider C, Möhring C, Zhou T, Mahn R, Bartels A, Praktiknjo M, Kornek MT, Toma M, **Schmidt-Wolf** IGH, Branchi V, Matthaai H, Kalf J, Strassburg CP, Gonzalez-Carmona MA. Alpha-Fetoprotein- and CD40Ligand-Expressing Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma. *Cancers (Basel)*. 2021 Jul 5;13(13):3375. doi: 10.3390/cancers13133375. PMID: 34282787; PMCID: PMC8269346.

IF: 6.1

- Sharma A, Tobar-Tosse F, Chand Dakal T, Liu H, Biswas A, Menon A, Paruchuri A, Katsonis P, Lichtarge O, Gromiha MM, Ludwig M, **Schmidt-Wolf** IGH, Holz FG, Loeffler KU, Herwig-Carl MC. PPAR-Responsive Elements Enriched with Alu Repeats May Contribute to Distinctive PPAR γ -DNMT1 Interactions in the Genome. *Cancers (Basel)*. 2021 Aug 7;13(16):3993. doi: 10.3390/cancers13163993. PMID: 34439147; PMCID: PMC8391462.

IF: 6.6

- Wu X, Sharma A, Oldenburg J, Weiher H, Essler M, Skowasch D, **Schmidt-Wolf** IGH. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation. *Front Immunol*. 2021 Oct 7;12:731767. doi: 10.3389/fimmu.2021.731767. PMID: 34691037; PMCID: PMC8529192.

IF: 8.8

- Sharma A, **Schmidt-Wolf** IGH. 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. *J Exp Clin Cancer Res*. 2021 Dec 9;40(1):388. doi: 10.1186/s13046-021-02184-2. PMID: 34886895; PMCID: PMC8662881.

IF: 11

- Zhang Y, Sharma A, Weiher H, Schmid M, Kristiansen G, **Schmidt-Wolf** IGH. Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials. *Cancers (Basel)*. 2021 Nov 29;13(23):6007. doi: 10.3390/cancers13236007. PMID: 34885117; PMCID: PMC8656601.

IF: 6.6

- Wang Y, Ge F, Sharma A, Rudan O, Setiawan MF, Gonzalez-Carmona MA, Kornek MT, Strassburg CP, Schmid M, **Schmidt-Wolf** IGH. Immunoautophagy-Related Long Noncoding RNA (IAR-lncRNA) Signature Predicts Survival in Hepatocellular Carcinoma. *Biology (Basel)*. 2021 Dec 9;10(12):1301. doi: 10.3390/biology10121301. PMID: 34943216; PMCID: PMC8698564.

IF: 5.0

- Schellenberger B, Heuser C, Diekmann A, Ansmann L, Krüger E, Schreiber L, Schnettler B, Geiser F, **Schmidt-Wolf** IGH, Ernstmann N. Questions and emotional expressions from patients and companions while participating in multidisciplinary tumor conferences in breast and gynecological cancer centers. *Patient Educ Couns*. 2021 Dec 17:S0738-3991(21)00787-4. doi: 10.1016/j.pec.2021.12.010. Epub ahead of print. PMID: 34953619.

IF: 3.4

- Li Y, Sharma A, Maciaczyk J, **Schmidt-Wolf** IGH. Recent Development in NKT-Based Immunotherapy of

Glioblastoma: From Bench to Bedside. *Int J Mol Sci.* 2022 Jan 24;23(3):1311. doi: 10.3390/ijms23031311. PMID: 35163235; PMCID: PMC8835986.

IF: 5.9

- Garofano F, Sharma A, Abken H, Gonzalez-Carmona MA, **Schmidt-Wolf** IGH. A Low Dose of Pure Cannabidiol Is Sufficient to Stimulate the Cytotoxic Function of CIK Cells without Exerting the Downstream Mediators in Pancreatic Cancer Cells. *Int J Mol Sci.* 2022 Mar 29;23(7):3783. doi: 10.3390/ijms23073783. PMID: 35409142; PMCID: PMC8998663.

IF: 5.9

- Li Y, Sharma A, Wu X, Weiher H, Skowasch D, Essler M, **Schmidt-Wolf** IGH. A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines. *Front Oncol.* 2022 May 11;12:713476. doi: 10.3389/fonc.2022.713476. PMID: 35646685; PMCID: PMC9130779.

IF: 5.7

- Wu X, **Schmidt-Wolf** IGH. An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile. *Front Immunol.* 2022 May 23;13:913123. doi: 10.3389/fimmu.2022.913123. PMID: 35677035; PMCID: PMC9170073.

IF: 8.8

- Zhao C, Wang Y, Sharma A, Wang Z, Zheng C, Wei Y, Wu Y, Liu P, Liu J, Zhan X, **Schmidt-Wolf** I, Tu F. Identification of the Integrated Prognostic Signature Associated with Immuno-relevant Genes and Long Non-coding RNAs in Acute Myeloid Leukemia. *Cancer Invest.* 2022 Sep;40(8):663-674. doi: 10.1080/07357907.2022.2096230. Epub 2022 Jul 11. PMID: 35770858.

IF: 2.4

- Schellenberger B, Heuser C, Diekmann A, Ansmann L, Krüger E, Schreiber L, Geiser F, Karger A, **Schmidt-Wolf** IGH, Milz K, Peisker U, Ernstmann N. Patient participation in multidisciplinary tumor conferences in breast and gynecological cancer care: How patient-centered is the communication? *Psychooncology.* 2022 Sep;31(9):1597-1606. doi: 10.1002/pon.5999. Epub 2022 Jul 16. PMID: 35793433.

IF: 3.9

- Słomka A, Wang B, Mocan T, Horhat A, Willms AG, **Schmidt-Wolf** IGH, Strassburg CP, Gonzalez-Carmona MA, Lukacs-Kornek V, Kornek MT. Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts? *Theranostics.* 2022 Aug 1;12(13):5836-5855. doi: 10.7150/thno.73400. PMID: 35966579; PMCID: PMC9373826.

IF: 11.6

- Wang Y, Setiawan MF, Liu H, Dakal TC, Liu H, Ge F, Rudan O, Chen P, Zhao C, Gonzalez-Carmona MA, Kornek MT, Strassburg CP, Schmid M, Maciacyk J, Sharma A, **Schmidt-Wolf** IGH. Regulator of G Protein Signaling 20 Correlates with Long Intergenic Non-Coding RNA (lincRNAs) Harboring Oncogenic Potential and Is Markedly Upregulated in Hepatocellular Carcinoma. *Biology (Basel)*. 2022 Aug 4;11(8):1174. doi: 10.3390/biology11081174. PMID: 36009801; PMCID: PMC9405539.

IF: 5.2

- Peng Y, Qi W, Luo Z, Zeng Q, Huang Y, Wang Y, Sharma A, **Schmidt-Wolf** IGH, Liao F. Role of 18F-FDG PET/CT in patients affected by pulmonary primary lymphoma. *Front Oncol*. 2022 Sep 14;12:973109. doi: 10.3389/fonc.2022.973109.

IF: 6.2

- Schellenberger B, Heuser C, Diekmann A, Ernstmann N, Schippers A, Geiser F, **Schmidt-Wolf** IGH, Scholl I, Ansmann L. How shared is decision-making in multidisciplinary tumour conferences with patient participation? An observational study. *Health Expect*. 2022 Dec;25(6):3297-3306. doi: 10.1111/hex.13638. Epub 2022 Oct 31. PMID: 36314056; PMCID: PMC9700138.

IF: 3.2

- Qin J, Sharma A, Wang Y, Tobar-Tosse F, Dakal TC, Liu H, Liu H, Ke B, Kong C, Liu T, Zhao C, **Schmidt-Wolf** IGH, Jin C. Systematic discrimination of the repetitive genome in proximity of ferroptosis genes and a novel prognostic signature correlating with the oncogenic lncRNA CRNDE in multiple myeloma. *Front Oncol*. 2022 Dec 20;12:1026153. doi: 10.3389/fonc.2022.1026153. PMID: 36605450; PMCID: PMC9808058.

IF: 6.2

- Zhang Y, Wu X, Sharma A, Weiher H, Schmid M, Kristiansen G, **Schmidt-Wolf** IGH. Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma. *Front Immunol*. 2022 Aug 25;13:925633. doi: 10.3389/fimmu.2022.925633. PMID: 36091050; PMCID: PMC9453234.

IF: 8.8

- Sharma A, Wüllner U, **Schmidt-Wolf** IGH, Maciacyk J. Marginalizing the genomic architecture to identify crosstalk across cancer and neurodegeneration. *Front Mol Neurosci*. 2023 Feb 27;16:1155177. doi: 10.3389/fnmol.2023.1155177. PMID: 36923654; PMCID: PMC10008880.

IF: 6.3

- Klassen D, Strauch C, Alteheld B, Lingohr P, Matthaei H, Vilz T, Gonzalez-Carmona MA, Hausen A, Gräßler M, Sharma A, Strassburg C, Kalff JC, **Schmidt-Wolf** IGH. Assessing the Effects of a Perioperative Nutritional Support

and Counseling in Gastrointestinal Cancer Patients: A Retrospective Comparative Study with Historical Controls. *Biomedicines*. 2023 Feb 17;11(2):609. doi: 10.3390/biomedicines11020609. PMID: 36831145; PMCID: PMC9953606.

IF: 4.7

- Vaseq R, Sharma A, Li Y, **Schmidt-Wolf** IGH. Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors. *Int J Mol Sci*. 2023 Mar 15;24(6):5626. doi: 10.3390/ijms24065626. PMID: 36982701; PMCID: PMC10054817.

IF: 6.2

- Monin MB, Gorny JG, Berger M, Baier LI, Zhou T, Mahn R, Sadeghlar F, Möhring C, Boesecke C, van Bremen K, Rieke GJ, Schlabe S, Breitschwerdt S, Marinova M, **Schmidt-Wolf** IGH, Strassburg CP, Eis-Hübinger AM, Gonzalez-Carmona MA. Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter? *J Gastrointest Oncol*. 2023 Jun 30;14(3):1218-1234. doi: 10.21037/jgo-22-1065. Epub 2023 Jun 26. PMID: 37435197; PMCID: PMC10331752.

IF: 5.6

- Sharma A, **Schmidt-Wolf** IGH. Tempering of exhausted T cells to comprehend their adaptive response for suitable clinical translation. *Cell Mol Immunol*. 2023 May 9. doi: 10.1038/s41423-023-01031-y. Epub ahead of print. PMID: 37161047.

IF: 22.1

- Wang Y, Sharma A, Ge F, Chen P, Yang Y, Liu H, Liu H, Zhao C, Mittal L, Asthana S, **Schmidt-Wolf** IGH. Non-oncology drug (metictane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells. *Front Oncol*. 2023 May 19;13:1157366. doi: 10.3389/fonc.2023.1157366. PMID: 37274234; PMCID: PMC10235775.

IF: 6.2

- Hu C, Liu M, Li Y, Zhao Y, Sharma A, Liu H, **Schmidt-Wolf** IGH. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer. *Front Immunol*. 2023 Jun 29;14:1213716. doi: 10.3389/fimmu.2023.1213716. PMID: 37457699; PMCID: PMC10346844.

IF: 8.8

- Günther M, Hentschel L, Schuler M, Müller T, Schütte K, Ko YD, **Schmidt-Wolf** I, Jaehde U. Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers. *BMC Cancer*. 2023 Jul 5;23(1):629. doi: 10.1186/s12885-023-11115-7. PMID: 37407982; PMCID: PMC10320985.

IF: 3.8

- Ge F, Wang Y, Sharma A, Jaehde U, Essler M, Schmid M, **Schmidt-Wolf** IGH. Computational analysis of heat shock proteins and ferroptosis-associated lncRNAs to predict prognosis in acute myeloid leukemia. *Front. Genet. Sec.*

IF: 3.5

- Yulu Wang², Qian Liu³, Zhehuang Luo⁴, Wanlin Qi⁴, Qingyun Zeng⁴, Huan Fu⁵, Jianlin He⁶, Ingo G H Schmidt-Wolf², Amit Sharma^{2,7}, Fengxiang Liao. A rare imaging presentation with multisystemic clinicopathological features of Langerhans cell histiocytosis: case report and literature review. *Medicine*. In press.

IF:.....

- Waysczak J..... Regulatory T cell inhibition by P60 combined with adenoviral AFP transduced dendritic cells for immunotherapy of hepatocellular carcinoma. *Immunological Investigations*. 2023. <https://doi.org/10.1080/08820139.2023.2261980>.

IF:.....

- Ge F, Wang Y, Sharma A, Jaehde U, Essler M, Schmid M, Schmidt-Wolf IGH. Computational analysis of hsp proteins and ferroptosis-associated lncRNAs to predict prognosis in AML patients. *Frontiers in Genetics*. 01 August 2023. DOI 10.3389/fgene.2023.1218276.

IF:.....

- Amit Sharma, Yulu Wang, Fangfang Ge, Peng Chen, Tikam Chand Dakal, Maria Stella Carro, Fei Li, Ingo G.H. Schmidt-Wolf and Jarek Maciaczyk. Systematic integration of m6A regulators and autophagy-related genes in combination with long non-coding RNAs (m6A-AR-lncRNAs) predicts survival in glioblastoma multiforme. *Scientific Reports*, in press

IF:.....

- Bingduo Wang, Aliona Wöhler, Johannes Greven, Rebekka J. S. Salzmann, Cindy M. Keller, Tobias Tertel, Qun Zhao, Ümit Mert, Klemens Horst, Markus Huber-Lang, Tom Erik Mollnes, Sebastian Schaaf, Robert Schwab, Cristian P. Strassburg, Ingo Schmidt-Wolf, Bernd Giebel, Frank Hildebrand, Veronika Lukacs-Kornek, Arnulf G. Willms and Mirosław T. Kornek. LiBOD – Liquid Biopsy in Organ Damage – ExoView® small extracellular vesicle chip-based assessment of polytrauma. *Frontiers Immunology*, in press

IF:.....

- Robert Mahn*¹, Oscar André Glüer*¹, Farsaneh Sadeghlar¹, Christian Möhring¹, Taoato Zhou¹, Thomas Anhalt¹, Malte Monin¹, Alexander Kania², Tim Glowka², Georg Feldmann³, Peter Brossart³, Jörg C. Kalff², Schmidt-Wolf IGH⁴, Christian P. Strassburg¹ and Maria A. Gonzalez-Carmona¹. First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison. *J of Hepatocellular Carcinoma*. https://www.dovepress.com/articles.php?article_id=89687.

IF:.....

- Jingjing Pu, Amit Sharma, Jian Hou, Ingo G.H Schmidt-Wolf. Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment. *BMC Medical Genomics*, in press
- IF:.....

- Jingjing Pu, Amit Sharma, Ingo G.H Schmidt-Wolf. Histone deacetylase 6: at the interface of cancer and neurodegeneration. Future Medicine. <https://www.futuremedicine.com/doi/10.2217/epi-2023-0373>

IF:.....

- Amit Sharma, Xiubao Ren, Antonio Rosato, Dario Sangiolo, Zibing Wang, Sarah Tettamanti , Yi Zhang, Eva Rettinger, Kevin Aaron Fenix, Roberta Sommaggio, Elisa Cappuzzello Ingo G.H Schmidt-Wolf. Cytokine-induced killer (CIK) cells, successes and challenges: Report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy. Cancer Immunology, Immunotherapy, <https://doi.org/10.1007/s00262-023-03605-1>, 2024

IF:.....

- Yutao Li, Amit Sharma and Ingo G.H. Schmidt-Wolf. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer. Molecular Cancer, in press
- Zhizhen Huang, Amit Sharma, Yulu Wang, Aifang Jin, Wanling Qi, Ingo G. H. Schmidt-Wolf, Qian Liu and Fengxiang Liao. Inferring the diagnostic potential of 18F-FDG PET/CT in post-renal transplantation from a unique case harboring multiple rare complications. Frontiers in Medicine, 2024, in press
- Peng Chen, Amit Sharma, Hans Weiher, Ingo G.H. Schmidt-Wolf. Biological Mechanisms and Clinical Significance of Endoplasmic Reticulum Oxidoreductase 1 Alpha (ERO1α) in Human Cancer. In press, JECCR.

IF 2023: 11.3

- Yutao.Li, Amit Sharma^{1,2}, Michèle J. Hoffmann³, Dirk Skowasch⁴, Markus Essler⁵ and Ingo G.H. Schmidt-Wolf¹. Synergistic effects of cannabidiol and cytokine-induced killer cells via the modulation of TRPV2 channel and intracellular p-ERK 1/2 expression on non-small cell lung cancer cells. Geplant Cell Death & Discovery. Frontier Immunology, in press
- 299 Abstracts
- 28 Book presentations
- 715 Presentations

Projects

Head of clinical trials in various clinical trials

Member of the protocol commission / study control group in numerous multicenter trials

Investigator for clinical trials according to GCP/ICH and head of clinical trials according to AMG

Management of the study center for clinical trials

Member of the Ethics Commission at the University of Bonn

Member of the Expert Group Oncology in the Expert Group Off-Label
- Application of Drugs outside the approved indication area of the
Federal Institute for Drugs and Medical Devices according to §35b
para. 3 SGBV

Memberships

Faculty Board

Structural and personnel commission of the medical faculty

Deputy Speaker of the working group on Financing Interdisciplinary
Care of the CCC Network of Top Oncology Centres of German
Cancer Aid

Tumor Center Bonn

Deputy in the senate commission for planning and finance

Deputy Chairman of the Scientific Expert Committee of the NRW
Cancer Registry

Other Relevant Information